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ABSTRACT
Gene medicines are modern tools for treating a wide variety of diseases in all age groups,
including patients with reproductive capability. As the action of gene medicines is directed at
the genome itself, the safety criteria of these drugs exceed those of conventional medicines. Our
aim was to study the distribution of clinical grade adenoviral transfer gene vectors in the female
reproductive tract and their effects on fertility and offspring. Gene vectors were administered
into the fetal exocoelomic cavity in rats and into uterine lumen in rabbits, and intravascularly
into uterine and ovarian arteries in rabbits using microsurgical and angiographical operative
methods. A LacZ marker gene and a suicide gene, thymidine kinase, were used as transgenes.
Baculoviruses and plasmid/liposomes were used to compare the effects between the vectors.
The materno-fetal leakage of the adenoviral vector seems to be prevented by the fetal
membranes, but transplacental escape of the gene vector may occur. After administration of
adenoviruses into the fetal exocoelomic cavity of rats the vector was blocked by a rodent fetal
membrane. In addition, intraluminal vector administration into pregnant rabbits did not affect
the fetuses. After intravascular gene transfer the transgene DNA was observed in the liver
samples of the offspring in subsequent matings, but the number of positive young declined over
time. Neither signs of vertical transmission nor gene expression in fetal organs were noted.
All ovarian and uterine tissues could be transduced with adenoviral vectors and the
transduction pattern varied with the administration route and stage of the reproductive cycle.
After intraluminal uterine gene transfer the transgene leaked into the endometrial stroma and
uterine muscular wall during the inactive stage. However, during the proliferative stage the
transduction was restricted to the dividing endometrial epithelial cells. Shortly after
intravascular administration of adenoviruses into pregnant rabbits a moderate transfection rate
was noted in the follicular cells and in the cells of the corpus luteum, in addition to a low
expression rate in the primordial oocytes in the ovaries. With thymidine kinase suicide gene
therapy morphological changes were observed in oocytes in histological stainings, but in long-
term follow-up no effect on fertility was observed and normal progeny were born from
subsequent matings of the treated rabbits. In non-pregnant rabbits the intravascular gene
transfer did not affect the oocytes, and transgene expression was restricted to the thecal and
stromal cells. With baculoviruses and plasmid/liposomes no transfection was noted in ovaries
and uteri, in spite of a relatively high transfection rate in primordial oocytes in pregnant rabbits
with plasmid/liposomes.
We conclude that the safety of adenoviral gene therapy in female reproductive organs
is good, because the exposure of rabbit and rat ovaries and uteri to adenoviral gene therapy did
not affect fertility or the germ line in long-term follow-up, despite high transduction efficiency
in uterine and ovarian cells being observed shortly after the gene transfer. However, the leakage
of the transgene into the offspring could not be excluded after large dose exposure via the
circulation, although no integration of the transgene into the genome was detected.
National Library of Medicine Classification: QZ 52, QU 470, QU 475, QZ 42, WP 565, WP 320
Medical Subject Headings: Gene Therapy/adverse effects; Genetic Vectors/adverse effects; Safety;
Fertility; Germ Cells, Ovary; Oocytes; Uterus; Adenoviridae; Baculoviridae; Plasmids; Transgenes;
Rabbits; Rats
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INTRODUCTION
Gene therapy is a promising tool in modern
medicine. Today, over 1300 clinical trials
have been performed or are ongoing
worldwide (http://www.wiley.co.uk/genether
apy/clinical/) and the first gene medicine for
treating cancer has already been licensed in
China (Peng, 2005). The distribution of
patients receiving gene therapy includes all
age groups and both genders, and the
spectrum of diseases which may be treated is
expanding. Also, the techniques for germ line
genetic engineering and fetal gene therapy
already exist.
As the actions of gene medicines are
targeted at the genetic machinery itself, the
safety criteria of these drugs exceed those of
conventional medicines. According to the
international advisory committees, such as
the European Medicines Evaluation Agency
(EMEA) and U.S. Food and Drug
Administration (FDA), the germ line effects
of gene medicine should be strictly decoded
before licensing the product, but the gene
medicine is allowed to enter into clinical
trials before these studies (Epstein et al.,
1999). In general, a stable germ line
alteration caused by gene therapy in humans
using current technology is considered as a
contraindication to the procedure (Wadman,
1998). However, despite the increasing
number of clinical trials, the scale of the
preclinical safety data of the possible effects
of gene therapy on the genital organs and
germ cells remains quite limited.
Viral vectors are commonly used as
vehicles in gene medicine. Adenoviral cancer
gene therapy is already in phase II/III clinical
trials for the treatment of many cancer types,
including terminal brain tumors, neck and
ovarian carcinoma (Immonen et al., 2004;
Raki et al., 2006; Reid et al., 2002; Yu and
Fang, 2007). Further, adenovirus-based gene
therapies may also be used in syndromes
affecting mainly young patients with
reproductive capability. In the future, the
adenoviral vectors, with their tendency to
induce transient gene expression, will be
alternative candidates for gene therapy for
benign obstetric and gynecological disorders,
such as impaired placentation, myomas, and
even contraception (Daftary and Taylor,
2003; Sharkey et al., 2005; Stribley et al.,
2002).
This study was done to define the
distribution of adenoviral gene transfer in the
female reproductive tract, and to assess the
actual risk of vertical transmission and effects
on the fetus in an animal model. In addition,
the suitability of adenovirus, baculovirus and
plasmid/DOTMA:DOPE vectors for gene
therapy in uterine and ovarian tissues was
evaluated. Both the effects of the stage of the
reproductive cycle and the administration
route on transfection efficiency and vector
distribution were studied by using pregnant
and non-pregnant rats and rabbits, and four
gene transfer routes. The distribution was
studied with a marker gene, which had no
therapeutic effects. Furthermore, the impact
of suicide gene therapy on reproductive
ability was evaluated with thymidine kinase,
hsv-TK, in combination with ganciclovir,
which is widely used in cancer gene therapy.
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REVIEW OF THE
LITERATURE
GENOME EVOLUTION, GENETIC
MANIPULATION AND ETHICS
Genetic manipulation and genome evolution
have many fundamental similarities. The idea
of gene therapy is to change the defective
part of the genetic machinery by delivering a
functional transgene into a cell. This can be
done by either by deliberately altering the
genetic sequences within the genome, or by
delivering genes into a cell as soluble, non-
chromosomal transgenes which don’t cause
any stable changes in the cell genome. In
nature the same processes, including both
transient and stable changes in genetic order,
frequently occur. As germ line cells are
concerned, these processes which change the
genome itself are evolutionary mechanisms
creating new genetic combinations.
Significant differences between genetic
manipulation and evolutionary mechanisms
are that the former process is much faster
than the latter, and with genetic manipulation
the effects are commonly directed to somatic
cells in one individual without affecting the
genetic evolution (Smith, 2003).
The first inheritable elements are
hypothesized to have appeared 3 800 million
years ago when the first living organism, a
prokaryotic cell possessing those elements
which enable the maintenance of genetic
information, came into existence (Hayes,
1996; Mojzsis et al., 1996). It took the next
2000 million years for eukaryotes to develop,
and the first mammals appeared not earlier
than 200 million years ago. Then, according
to current scientific views, the natural
selection of developing genetic combinations
led to creation of rodents 600 000 years ago:
the dawn of the era of a wise human, Homo
Sapiens Sapiens, is estimated to have
occurred only 50 000 years ago.
The mystery of life has inspired
scientists from the ancient philosophers to
today’s geneticists. Concerning the history of
genetics, the inheritable element theory was
first demonstrated by Gregor Mendel in 1865
(Bennett, 1866). Thereafter it took almost 90
years before the structure of these elements,
the DNA, was introduced by Watson and
Crick in the 1950’s (Watson and Crick,
1953). During the same time the first
innovations in gene therapy were made, as
Avery, MacLeod and McCarthy discovered
that nucleic acids can be used for transferring
a trait (Lederberg, 1994). Still, it took another
50 years before the human genome was
sequenced, revealing many structural facts of
the history of our genome and the
evolutionary mechanisms (Lander et al.,
2001). However, from then on, genetic
research rushed forward revealing also many
molecular basics of genetic engineering in the
process (Friedmann, 1992).
Viruses are natural gene transfer
vehicles which have shaped cell genomes
during evolution by integrating their genes
into the genome of an organism (Podolsky,
1996). Virus-like elements comprise a large
portion of human genomic DNA. In actual
fact, in the human genome the critical DNA
areas, the exons and regulatory sequences,
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occupy less than 5 % of the genomic DNA
(Venter et al., 2001). Mobile, or transposable,
elements are DNA sequences that act as
inborn viruses in a cell’s genome; they have
the ability to integrate into the genome at a
new site (Yoder et al., 1997). Usually they
are transcriptionally silent and some of these
elements of genome, called transposones,
have strong similarities with the retrovirus
genome, called retrotransposones (Kazazian,
2004). Their recognizable remnants are
estimated to comprise as much as 10-45 % of
the human genome and hence these elements
are considered to have a major role in
shaping mammalian genomes (Deininger et
al., 2003; Goff, 2001; Hughes and Coffin,
2001; Hughes and Coffin, 2005).
In addition to the changes occurring
in the organization of the DNA sequence
itself the cell accommodates to changing
conditions by controlling gene expression.
For example the ability of a multicellular
organism to produce specific types of cells
during development requires coordination of
multiple genes. The complex roles of gene
regulatory factors, including proteins and
regulatory RNAs, are currently widely
studied. One of these regulatory mechanisms
is called epigenetic gene silencing, that is to
say changes in gene expression that are stable
between cell divisions, and sometimes
between generations, but do not involve
changes in the DNA sequence of the
organism. The post-transcriptional form of
epigenetic silencing is known as RNA
interference (RNAi) in which endogenous
microRNA particles (miRNAs) play a role in
transcriptional genetic silencing by DNA
methylation and heterochromatin formation,
at least in lower animals (Dawe, 2004;
Lippman and Martienssen, 2004; Lippman et
al, 2004). Moreover, regulation of gene
expression during development seems to
involve regulative miRNA molecules that are
likely to have a significant role in a wide
range of developmental processes in animals
(Carrington and Ambros, 2003).
Additionally, the RNAi is also the cell’s
inborn defence mechanism against viruses, as
viral genes are silenced by these mechanisms
(Carrington and Ambros, 2003). Methods of
RNAi are also used in gene therapy.
Exogenous small interfering RNAs (siRNAs)
are developed for treating syndromes in
which silencing of gene expression is needed,
for example to inhibit growth factor
production in cancer cells (Novina and Sharp,
2004).
During evolution the genomes have
also been modified by direct changes in germ
line DNA in addition to these complex
epigenetic changes. The mutations and
insertions have occurred over a long period of
time, and improper recombinations have been
eliminated by natural selection. The number
of new mutations, such as point mutations, or
endogenous and viral insertions, in one
individual human genome has been estimated
to be as many as 100 (Kondrashov, 1995). In
addition, in other approximations it has been
stated that there can be 75 mutations derived
from the germ cells of an individual man
(Kazazian, 1999). In addition to the
epigenetic mechanisms, these endogenous
genetic modifications have modeled both the
genome and the gene expression during
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evolution. However, the inadvertent germ
line effects caused by gene therapy are
raising questions regarding the unpredictable
effects on future generations.
Ethical considerations of human
genetic manipulation reveal a multilevel
problem with various viewpoints, including
the concerns of the patient, the scientific
organization developing the treatment, the
general opinions from the surrounding
society and not least, the effects of
manipulation in future generations. The
regulatory authorities have published some
recommendations for preclinical safety
evaluation of gene transfer products, but
specific guidance is not available (Christ,
2002). The FDA has recommended that
rather than setting specific directives, policy
decisions about the risks of genetic insertion
should be based on disease severity, age, life
expectancy and reproductive status, as well as
vector biology and animal safety data
(Epstein et al., 1999). In somatic gene
therapy the main risks are uncontrollable
infection involving gene delivery vectors and
mutagenesis caused by integrating
transgenes. Another concern arises from the
risk of vertical transmission to germ line cells
affecting future generations. If the latter risk
is included, the associated ethical
considerations of the treatment go beyond an
individual’s consent and ought to involve the
deliberations of an ethics committee. This
raises the issue of the acceptable level of
transgene insertions in the germ line during
gene therapy (Smith, 2003). However, it
should be pointed out that many conventional
drugs, such as cyclophosphamide, and
common chemicals in our environment, such
as tobacco smoke and ethanol, are also
genotoxic and may result in inadvertent
mutagenesis in the germ line (Dellarco, 1993;
DeMarini, 2004; Waters et al., 1999).
The transgenic techniques for
animal germ line manipulation are already
developed and there are no fundamental
reasons to suggest that these techniques could
not also function with human germ cells.
Accordingly, there is the question of the
benefits that germ line manipulation could
evoke in future generations suffering from
hereditary genetic diseases. The National
Institute of Health Recombinant DNA
Advisory Committee (RAC) in the USA has
so far refused to consider germ line gene
therapy proposals and indicated that
intentional germ line alteration by gene
therapy is unacceptable in humans (Wadman,
1998). Indeed, the possibility that somatic
gene therapeutics could find their way into an
individual’s germ line is a contraindication to
the procedure (Editorial, 1999).
In the future the question of ethical
acceptance of some degree of the inadvertent
germ line effects during somatic therapies
needs to be considered. Furthermore, the
same questions are faced in the exploration of
germ line genetic engineering for treatment
of diseases. As the catalogue of genetic
diseases ranges from pernicious syndromes to
minor disorders such as color blindness,
therapeutic genetic manipulation resulting in
germ line transmission represents the thin end
of the wedge. On the contrary, if speculating
of the manipulation of phenotypic traits, such
as height or intelligence, the eugenic horror
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scenario may prevent the medically useful
forms of genetic manipulation as gene
delivery technology improves (Smith, 2003;
Whittaker, 2007).
FEMALE REPRODUCTIVE
ORGANS AND DIFFERENCES
BETWEEN SPECIES
Overview of the development of fetal
cavities, ovaries and uterus
The mammalian embryonic development
proceeds in a comparable order in different
species. Consequently, similar-kinds of cell
lines and cell migrations are found in each
developmental stage in the embryos.
However, when drawing conclusions from
the results obtained from an animal model
and comparing them with the human
situation, some basic differences in fetal
development between these lower laboratory
animals, such as rabbits and rats, and more
developed species, such as humans should be
noted. In addition, the developmental
timetable between these species differs
radically: in humans the pregnancy lasts
about nine months, whereas the respective
durations in rabbits and rats are 30 and 21
days.
The early embryonic development
of fetal cavities and the physiology of
membrane structures in humans differ from
the ones in rodents. In humans, the embryo
develops directly into the cavities surrounded
by the fetal membranes, the inner amnion and
the outer chorion. The space between these
two membranes is called the exocoelomic
space (EC) and in humans it gradually
atrophies during early development. In
contrast, at the start of the membrane
formation in the rat the cavities are in a row,
and during complete inversion the fetus rolls
into the cavities during day 10 post coitus
(p.c.), drawing the membranes around itself
(fig. 1) (Hebel and Stromberg, 1986;
Mossman, 1987). Moreover, the chorion in
rats lasts throughout fetal development and a
third membrane, outside the chorion and not
found in humans, called the Reichert’s
membrane, is formed during early
development. The Reichert’s membrane
ruptures and retracts around the placenta
before birth (Kaufman and Bard, 1999).
The development of the
reproductive organs begins in the first
trimester of pregnancy, i.e. on the seventh
week in humans and during the first few days
in smaller mammals. In the absence of
testosterone, the uterus, oviduct and upper
part of the vagina develop from the Müllerian
duct (Merchant-Larios, 1978). In humans,
having the more advanced model of uterus,
these two ducts fuse together forming a single
uterine lumen, but in rats and rabbits a less
advanced duplex uterus develops with two
cervical openings into the vagina (Hardisty,
1978).
The ovaries develop from two cell
lines - stromal connective tissue and germ
cells. The cells in the gonadal ridge form the
stromal tissue of the developing ovaries,
whereas the germ cells are derived from the
yolk sac endoderm. They migrate into the
gonadal ridge from the fetal end of allantois
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via the dorsal mesentery and body wall (fig
1). The allantois is floating in the
exocoelomic cavity. The migration takes
place during the fifth week in humans,
between days eight to thirteen in rats and
between the ninth to sixteenth days p.c. in
rabbits (Hardisty, 1978). After migration the
germ cells multiply by mitosis. Large
intercellular bridges exist and despite the
high rate of apoptosis up to one million germ
cells will form by the time of birth. However,
only a minor subpopulation of all these cells
manages to develop into mature oocytes
(Gondos, 1978).
The transformation of the diploid
germ cells into haploid oocytes by the first
Figure 1: Organisation of rat fetal membranes and process of complete inversion.
During early fetal development until day 9 p.c. in rats the fetal cavities are in a row and surrounded
by Reichert’s membrane. During day 10 the fetus rolls into the cavities. After this process, called
complete inversion, the order of the cavities resembles the membrane organization in a human fetus,
excluding the Reichert’s membrane which is found only in rodents. In rodents the umbilical cord is
formed by allantois (indicated by a), which passes through the exocoelomic cavity (indicated by a
star) and implants in the opposing wall forming a connection to the developing placenta (p). The
germ cells migrate from the fetal end of the allantois into genital ridges during days 8 and 13 p.c. in
rat. Copyright © 2008 Anniina Laurema. All rights reserved.
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meiotic division begins during the 12th
gestational week in humans, and at birth all
surviving oocytes have completed their first
stage of meiosis. In rabbits this process of
oogenesis is not initiated until the first day of
life and all germ cells have undergone the
first meiotic division at the age of three
weeks (Baker, 1982). In humans, the first
meiotic division of one germ cell takes
approximately three months to be completed,
but in rabbits only about ten days are needed
(Gondos, 1978). The cell cycle of oocytes is
arrested at this stage of first meiosis. The
oocytes will remain at this stage until they
have passed through the growing phase
during follicular development. Thus, DNA
replication in oocyte takes place only during
prenatal period and then after fertilization,
and during adulthood only DNA repairing
processes occur in the oocyte genome.
Therefore, after meiotic division the oocyte
genomic DNA is in stabile stage thorough the
adult lifetime until fertilization.
The stromal tissue around the germ
cells also undergoes developmental
transformation during oogenesis. The
granulosa cell layer encloses the single germ
cells and breaks the multiple intercellular
connections between the germ cell islands.
Afterwards, the large intercellular bridges
between the germ cells are replaced by
smaller ones between oocytes and granulosa
cells. Around the granulosa cells the
follicular basement membrane disconnects
the developing primordial follicle from the
surrounding stromal cells. At the time of
birth, all human and rat oocytes are in the
primordial follicle stage, but in rabbits the
same developmental stage is not reached until
the first week of life (Peters, 1978).
The immune system of the
developing fetus does not prevent the viral
action during early pregnancy.
Immunological complement system begins to
develop in the late first trimester, by which
time the fetus produces all the essential
components. Until then, the fetal immune
system is maintained by the IgGs of maternal
origin, that are transported across the placenta
(Sadler, 2004).
Macroanatomy of rabbit gonadal organs
and reproductive cycling
During evolution the types of uteri and
gonadal functions have evolved to meet the
reproductive needs of individual species.
However, similar features are found in the
structure and function among many
mammals. The rabbits have a rudimentary,
duplex uterus suitable for carrying multiple
fetuses (fig. 2, page 20). In contrast, the
highly developed simplex human uterus is
designed to carry a single fetus (Finn and
Porter, 1975).
The reproductive cycling and the
changes in the gonadal organs are regulated
by a complex synergism of both hypophyseal
protein hormones and gonadal steroid
hormones. The regulation of the hormonal
balance in the pituitary-gonadal axis includes
both modification of hormone synthesis and
the content of their receptors. In general,
follicle stimulating hormone, FSH, from the
hypophysis and estrogen secreted by
follicular cells in the ovary mainly function
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during the first half of the reproductive cycle
enforcing follicular growth and endometrial
proliferation. Ovulation is caused by a peak
in the secretion of luteinizing hormone, LH,
from the hypophysis, and progesterone from
the luteal glands maintains the endometrial
activity until, in the case of fertilization,
chorion gonadotropins of placental origin
 continue the maintenance (Richards, 1978).
The immunological changes during
reproductive cycling and pregnancy include
complex cascades of multiple immunological
transmitters and functions of immune cells
that are regulated by gonadal hormones and
chemokines (Kayisli et al., 2002; Schulke et
al., 2008). During pregnancy the maternal
Figure 2: Schematic figure of the female rabbit reproductive organs and their vasculature.
Left: Anatomy during non-pregnant period. Right: Anatomy during pregnancy, day 14 p.c.
Copyright © 2008 Anniina Laurema. All rights reserved.
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immune system develops a partial
immunologic tolerance to allow the foreign
fetal cells to penetrate into the endometrium
without rejection, but the general immune
response is not significantly reduced in
comparison with that in the non-pregnant
state (Thellin et al., 2000). The imbalance in
the regulation of maternal immunological
reactions during pregnancy leads to obstetric
disorders, such as preecplampsia and early
spontaneous abortion (von Rango, 2008).
Moreover, these immunological aspects may
have an impact on the reception of other
foreign material, such as infectious agents
used in gene therapy, in the maternal
reproductive tract during implantation and
pregnancy.
The cyclic alterations in
reproductive tissues during certain stages of
reproductive cycling differ between species.
In humans, ovulation occurs spontaneously,
whereas in rabbits neural excitation of
vaginal nerve-endings by coitus is needed to
induce ovulation. Additionally, in rabbits
hormonal treatment or external stimulation is
needed for endometrial proliferation, whereas
in humans the endometrium proliferates,
hypertrophies, differentiates and then
degenerates by decidual reaction once in each
reproductive cycle. In humans the period of
one reproductive cycle is about one month
and the entire follicular trajectory takes at
least three months (Macklon and Fauser,
1999). However, rabbits have a continuous
reproductive ability under suitable conditions,
without any exact estrous cycling. The antral
follicles wax and wane every 7-10 days and
one reproductive cycle takes 16-18 days: this
period consists of follicular maturation for
12-14 days, and early development of
follicles for four days. During these four days
ovulation does not occur (Hamilton, 1951;
Schlolaut, 1985). Ovulation takes place
within 10-12 hr following coitus (Hamilton,
1951). If the fertilization doesn’t occur, a
status called pseudopregnancy results which
lasts 17 days and includes the same kind of
hormonal and physiological changes as in
normal pregnancy (Schlolaut, 1985).
Similar macroscopic ovarian
structures including the growing follicles and
luteal glands are found in both species. In the
multiovulatury rabbit many growing follicles
reach the mature stage, whereas in humans
only one or two leading follicles survive.
However, the mature follicle ruptures
spontaneously in every reproductive cycle in
humans, while in estrous rabbits the mature
follicles undergo atresia without an inductive
stimulus (Lawn, 1973).
The developmental differences
between the human and rabbit uterus also
lead to special features in pregnancy in both
species. An unviable fetus in a simplex uterus
is wasted by abortion, but in the rabbit the
fetuses are in a row and can hardly be aborted
individually. Therefore, until day 19 of
gestation in rabbits, the dead fetuses are
absorbed by enzymatic activity of the
endometrial cells (Cheeke, 1987). In addition,
the structure of the placenta is a rudimentary
model in rabbits, whereas in humans the
arrangement of the placental vessels is
considered to be the most highly developed
among mammalian species (Heikkila, 2003;
Mossman, 1987).
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Microanatomy of uterine and ovarian
tissues
Uterus. The corpus of the uterus comprises
of the uterine muscle, called myometrium,
and the endometrium. The myometrium is
surrounded by the peritoneum and consists of
longitudinal and circular layers of smooth
muscle cells (fig. 3). The endometrium
consists of connective stromal tissue,
endometrial glands and epithelium lining the
uterine lumen. The endometrial epithelial
cells are tightly connected to each other and a
basement membrane is found below the
epithelial cells lining the stromal cells (Finn
and Porter, 1975).
Cyclic activation of the
endometrium is closely correlated with
ovarian cycling, which in human begins
spontaneously and in rabbits from the
induced ovulation. In humans the
endometrium proliferates by mitotic activity
during the first half of endometrial cycle.
During the second half, after ovulation, the
cells in the endometrial epithelium and
stroma start to differentiate. If fertilization
occurs, the endometrial proliferation goes on
and true decidua forms. Otherwise, the
stromal reaction regresses and menstruation
ensues (Finn and Porter, 1975).
In rabbits the rapid morphological
changes during endometrial proliferation
after induced ovulation correspond to the
proliferation occurring spontaneously in
humans (Lawn, 1973). Until the time of
coitus the endometrial surface is smooth with
many shallow glandular openings (fig. 3).
Two days p.c. the folding has increased and
proliferation of endometrial cells is rapid
with numerous mitoses in the epithelial cells
and uterine glands. During day four p.c. there
is a marked branching of the mucosal folds
and the endometrium shows a labyrinthine
morphological structure with many deep
glands (fig. 3).
Figure 3: Histological cross-section of rabbit uterine
tissues. Outer longitudinal and inner circular
smooth muscle layers surround the endometrium
facing the uterine lumen. During the active stage,
the labyrinthine structure of the deep uterine glands
can be seen (upper figure of endometrial glands) but
in inactive endometrium the glands are rare (lower
figure of endometrial epithelium).
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If fertilization occurs, the fetal trophoplastic
cells invade the endometrium during day
seven p.c. and placentation begins (Suzuki
and Tsutsumi, 1980). Otherwise, during
pseudopregnancy, which lasts for 17 days in
rabbits the endometrium gradually
degenerates by lymphocyte activity and
remains in the follicular phase until the next
hormonal stimulus (Lawn, 1973; Schlolaut,
1985).
The endometrium is directly
exposed to the surrounding environment and
to infectious agents via the vagina and cervix.
Reproductive tract mucins such as
Muc1/episialin play key roles in protection
from microbial infection and also
implantation related events (DeSouza et al.,
1999). The expression of Muc1 is down-
regulated during implantation, which may
enhance the infectivity of viral agents
reaching the uterine lumen during the first
trimester of pregnancy.
Ovary. The ovary can be divided
into two areas, the cortex and the medulla,
and the surface epithelium surrounding the
whole organ. The medulla consists mainly of
connective tissue, the stromal cells and
invading lymphatic and blood vessels, and
nerves. In rabbits numerous large glandular
formations of unknown origin, named
interstitial glands in the literature, can also be
found (Duke, 1978). The cortex contains the
gonadal structures such as follicles in all
maturation stages, corpora lutea and other
glandular elements including their remnants,
the corpora albicantia.
In the absence of ovulation in
rabbits a series of follicles in all
developmental stages can be found, with
numerous atretic follicles among them
(Hamilton, 1951).
Oocytes and follicular development
A normal animal cell is 10-30 µm in diameter
and surrounded by a 4-5 nm thick double
lipid layer, the cell membrane (fig 4, page
23). Proteins embedded into the membrane
connect the intra- and extracellular
environments by various exchange
mechanisms. Inside the cell the genetic
material is in the nucleus which is surrounded
by the nuclear envelope consisting of two
membrane layers.
The messenger RNA (mRNA)
transcribed from the nuclear DNA is
transported through nuclear pore complexes
into the cytoplasm, in which the ribosomes
on the endoplasmic reticulum synthesize the
proteins from amino acids according to
mRNA information. The proteins assume
their final form and are transported to their
destination through a membrane labyrinth
called the Golgi apparatus. The energy for the
process is produced by oxidation in the
mitochondria (Pollard and Earnshaw, 2002).
Oocyte. A germ cell functions in
much the same way as a normal animal cell
but some basic differences should be pointed
out. Firstly, they are pluripotent. Secondly,
they spend most of their lifetime as haploid
cells after meiotic division and thirdly, after
their activation at the beginning of final
maturation they are protected from the
outside environment by the Zona Pellucida
(ZP) glycoprotein layer.
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The germ cells are characteristically spherical
and large in size having sparse lipid reserves
and a scanty endoplasmic reticulum
(Hardisty, 1978). Substances may reach the
oocyte via intercellular space and
endocytosis, or via follicular cells by
membrane diffusion through heterologous
gap junctions and desmosomes between
oocytes and follicle cells (Senbon et al.,
2003; Zamboni, 1974). Also, in some areas
the oocyte is in direct contact with the
follicular basement membrane and therefore
more exposed to ovarian stroma and blood
vessels (Baker, 1982; Tsafriri, 1978). From
the literature, no comprehensive data of the
oocyte cell surface receptor morphology is
available.
As a female becomes sexually
mature, a small number of arrested oocytes
mature periodically. In growing oocytes the
cell organelles increase both in amount and
size. Also, the oocyte itself grows from 30-50
µm to 100 µm in humans, and from 30 µm to
90 µm in rabbits (Hutt et al., 2006). The 10-
15 µm thick ZP is formed around the growing
oocyte, and cytoplasmic projections of 50-
180 nm diameter protrude through the ZP and
perivitelline space from both the oocyte and
the granulosa cells (Vanroose et al., 2000;
Zamboni, 1974). These oocyte-follicle cell
connections facilitate exchange of small
substances and enable active bidirectional
communication between the cells through
small size gap junctions (Anderson and
Figure 4: Schematic figure of an animal cell.
Modified from http://encarta.msn.com/media_461540224/animal_cell.html
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Albertini, 1976; Baker., 1982; Matzuk et al.,
2002). As the maturation process proceeds,
less projections traversing through the ZP can
be observed (Tsafriri, 1978; Vanroose et al.,
2000)
ZP is a unique structure protecting
the oocyte from mechanical damage and
acting as a species-specific barrier for sperm
during fertilization. This 10-15 µm thick
amorphous extracellular matrix surrounding
the oocyte plasma membrane is made up of a
network of thin polypeptide filaments,
glycoproteins, which also act as a receptor for
sperm (Michelmann et al., 2007; Wassarman
et al., 1999). The space between the ZP and
oocyte cell membrane is called the
perivitelline space. ZP has relatively large
pores, through which even immunoglobulins
may pass. However, the ability of molecules
to pass the porous ZP depends both on the
size of the molecule and on biochemical
properties such as surface charge (Sinowatz
et al., 2001; van den Hurk and Zhao, 2005).
Moreover, viruses are known to get through
the ZP, possibly depending on the action of
viral enzymes (Austin, 1982). During
fertilization a secretory discharge from the
oocyte, called cortical reaction, occurs after
sperm fusion and causes hardening of the ZP.
Thereafter, the increased resistance of the ZP
to proteolytic digestion by acrosomal reaction
acts as a block against polyspermy (Green,
1997; Vanroose et al., 2000).
Follicular development. The follicle has two
major roles in the ovarian function, which are
the facilitation of oocyte maturation and
release, and steroidogenesis (Lunenfeld et al.,
1976). The folliculogenesis starts in humans
during fetal time but in rabbits it starts as late
as between 11th and 17th day of postnatal life.
In resting stage, the oocytes without ZP are
surrounded by tight follicular basement
membrane and flat pregranulosa cells in
primordial follicles (fig 5: 1, page 26).
(Peters, 1978; Rodgers et al., 1999).
At the time of menarche the
hormonal status of the female changes and
raised follicle stimulating hormone, FSH and
luteinising hormone, LH levels cause the
follicular elements of the ovary to grow. In
rabbits the complete follicular maturation
takes 18 hours. First, in the primary follicle
the flat pregranulosa cells of the primordial
follicle change to columnar granulosa cells
and the formation of the ZP begins (fig. 5: 1-
3). Next, the surrounding stromal cells start to
differentiate into hormone producing theca
cells forming the two theca cell layers,
interna and externa, around the follicle (fig.
5: 3). These theca cells act synergistically
with granulosa cells to achieve efficient
estrogen synthesis.
In the formation of the secondary
follicle, the granulosa cells multiply and form
layers around the oocyte (fig. 5: 3). Then
large, intercellular fluid-filled spaces are
formed between the multiplying granulosa
cells. Inside this follicular structure, which is
called the antral follicle, the oocyte with
surrounding granulosa cells, called cumulus
oophorus, is floating (fig. 5: 4). The follicular
fluid accumulates in the follicular antrum and
the ripe, Graafian follicle often bulges out of
the ovarian surface and is highly vascularized
(fig. 5: 5) (Bjersing, 1978; Burden, 1978;
Tsafriri, 1978).
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Follicular atresia, the process during which
the oocyte is disposed of by cell death, is a
normal occurrence in all follicular maturation
stages (fig. 5: 6). During the mature period
10.5 % of all small follicles are atretic, and as
the percent of atrophic follicles among the
larger ones reaches 62 % in rabbit and 50-75
% in human, the total loss of follicles during
Figure 5: Rabbit ovary and histological figures of follicular development.
Numerous oocytes in primordial follicles are found in a fertile rabbit ovary (1). At the beginning of
maturation the oocyte starts to grow and the surrounding granulosa cells become cuboidal (2) and
begin to form layers (3). A fluid filled follicular antrum develops between the granulosa cells and
the surrounding stromal cells differentiate into thecal cells (4). The ripe tertiary follicle bulges out
from the ovarian surface (5). If coitus doesn’t occur, the follicles atrophy (6) whereas after coital
stimulus and ovulation the follicular cells differentiate into the luteal gland (7). Scale bars in
histological figures 100 µm.
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reproductive life ranges from 77-99.9 %.
Macrophages and leukocytes, as well as
granulosa cells, remove the degenerating
oocytes. The time needed for elimination of
atretic follicles depends on the follicle size,
as small follicles are eliminated within hours
and large follicles within days in rabbits, and
within weeks in larger animals. The
regulatory mechanism leading to follicular
atresia and the process of selection of
remaining follicles remains unknown
(Byskov, 1978).
The exact molecular basis of
ovulation are not known, but hormonal
changes result in partial degradation of the
follicular wall and induce an acute
inflammatory reaction resulting in histamine
release, leukocyte migration and activation of
prostaglandins. Together these changes lead
to rupture of the follicular wall and expulsion
of cumulus oophorus from the follicle
(Espey, 1978). The granulosa cells of the
ruptured follicle lutheinize and form the
luteal gland (fig. 5: 7).
The vascular system of reproductive
organs
The inner reproductive organs in both rabbits
and humans receive their blood supply from
two bilateral pairs of main arteries, the
ovarian and uterine arteries (see fig. 2, page
20). However, the circulation of the
reproductive system is well established and
blood flow through one of those four arteries
is sufficient for efficient blood supply. The
microvasculature may undergo big changes in
their diameter and spiral form, and in the
morphology of the blood vessel wall during
female lifetime (Ellinwood et al., 1978).
The ovary is a highly vascularized
organ. The blood flow comes straight from
the aorta through the cephalic ramus of the
ovarian artery running parallel with the
ovarian vein via the suspensory ligament of
the ovary (see fig. 2, page 20). The caudal
ramus of the ovarian artery feeds the
oviductal area. In humans the ovarian vein
forms a plexus around the ovarian artery but
in rabbits these vessels are never closer than
1 mm to each other. Once through the ovarian
hilus the artery splits into numerous spiral
structures and then branches into small
arteries forming the microvasculature of the
ovary.
Changes in the microvasculature
occur during the different stages of ovarian
cycling. The architecture of small spiral
arteries can vary a lot depending on the
follicular structure. From the spiral arteries,
straight branches enter into growing follicles
and form a rich capillary network around the
basement membrane surrounding the follicle
(Macchiarelli et al., 1992). This capillary
plexus beneath the theca cell layer nourishes
the whole follicle including the oocyte, and
becomes more prominent parallel to the
follicular growth. Also, rich lymphatic
networks are found around large follicles and
corpus luteum. After ovulation these
capillaries dilate and invade the emerging
corpus luteum, and during pregnancy this
structure receives the majority of the ovarian
blood flow. Multiple arteriovenous shunts
also play a key role in changing the blood
flow into different ovarian structures during
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the reproductive cycle (Ellinwood et al.,
1978).
Ovarian capillaries have high
permeability and even high-molecular-weight
compounds are able to pass through the
vascular endothelium. However, a follicular
barrier prevents substances from reaching the
oocyte surroundings, as only low-molecular-
weight compounds are found in follicular
antrum (McNatty, 1978).
The uterine artery branches from the
internal iliac artery and separates into
multiple rami running through the uterine
ligament before penetrating into the uterine
muscle (see fig. 2, page 20). It forms rich
plexuses on both sides of the human single
uterus and on one side on both horns of the
rabbit double uterus. The uterine
endometrium receives its blood supply from
two types of arteries, the basal arteries
supplying the basal areas of the stroma and
long spiral arteries vascularising the
superficial and functional stromal layers and
the epithelium. The pregnancy dramatically
affects uterine blood flow by increasing the
vascular permeability and enlarging the
vessel diameter (Finn and Porter, 1975).
There are quite large utero-ovarian
anastomoses between the two arteries in most
species. In rabbits the ovary gains 90 % of its
blood flow through the ovarian artery and
only 10 % flows through the uterine artery. In
humans the ratio is not known. Also, the
vasculature of nonparous individual differs
from parous ones. During pregnancy the
blood flow through the ovarian artery and
utero-ovarian shunt compensates for the
increased need of the growing uterus and
fetuses (Ellinwood et al., 1978).
GENE TRANSFER VECTORS AND
THEIR DISTRIBUTION IN THE
REPRODUCTIVE TRACT
Overview of gene transfer vectors
Gene transfer vectors are vehicles for
delivering the therapeutic gene into a target
cell. The features of both the gene vector and
the target organism affect the success of the
delivery. Immune reactions against the gene
vector, poor cell penetration, low level of
expression of the therapeutic gene and
mutagenic aspects are basic problems in
current in vivo genetic engineering. Although
the molecular mechanisms inside and outside
the cell are widely studied, a lot of questions
concerning the low efficiency remain
unanswered.
With various gene vectors both
short-term and long-term therapeutic effect
can be achieved, depending on the ability of
the vector to incorporate the transgene into
the host cell genomic DNA (Walther and
Stein, 2000). In addition, the vectors may be
classified as viral and non-viral vectors, the
former based on recombinant wild type
viruses having an in-born tendency to infect
cells and the latter being chemical
constructions containing various surface
elements enclosing the transgene. In viral
vectors the normal viral genes are partly
replaced by the therapeutic transgene. Most
of the recombinant viral vectors used today
are replication deficient as the machinery for
replication is removed from the viral genome,
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but replicative vectors are increasingly being
developed for therapeutic use (Hedley et al.,
2006).
The stable expression is achieved by
integration of a transgene into the host cell
genome and the short-term, transient
expression occurs from loose episomal, non-
integrated DNA sequence.  In general, the
transient gene expression begins shortly after
the gene transfer and continues for up to a
few weeks before the episomal DNA is
degraded; whereas the stable expression of
integrated transgene begins a few weeks after
the gene transfer and in an optimal situation
goes on throughout the cell’s life span. For
example, the maximum expression of
transgene of the two commonly used
integrating vectors, lentivirus and adeno
associated virus, AAV, takes 3-6 weeks,
whereas with the non-integrating
recombinant adeno- and baculovirus the
transgene expression reaches its maximum
level a few days after the gene transfer
(Walther and Stein, 2000). The transgene
protein production of the non-viral vectors
follows the same pattern as in non-integrating
viral vectors, in spite of artificial
chromosomes which have enabled stable
expression (Co et al., 2000).
In the mission of successful delivery
of the transgene DNA into the target cell the
gene vector has to penetrate through the cell
membrane, transport the DNA into the
nucleus through the cytoplasm and nuclear
envelope, and finally get the gene product
expressed using the enzymatic machinery of
the cell (Greber et al., 1997; van Loo et al.,
2001). Both the characters of the vector and
the target cell affect such successful
transduction cascades. The cell surface
receptors are needed for virus binding and
internalization into the cell by endocytotic
activity.  In the cytoplasm, for the uncoating
of the vector particle and transportation of the
vector capsid to the nucleus, the cell’s own
machinery is utilized. Moreover, viral vectors
carrying RNA should have their genome
transcribed into DNA before proceeding in
the infection cascade (Goff, 2001).
When reaching the nuclear
envelope, the interaction with the nuclear
pore complex is needed for the delivery of
the transgene into the nucleus. Actually,
some viruses, including the retroviral vectors,
do not have the capability to pass their
genome through the nuclear envelope and the
degradation of this membrane structure
during cell division is needed for successful
infection (Whittaker et al., 2000). After
arriving into the nucleus, the viral genome
may be transcribed episomally, i.e. from
extra-chromosomal DNA, or it may integrate
into the host cell genome depending on the
vector type.
Vectors for transient gene expression
The transient gene vectors usually have high
infectivity and they can be produced in high
titers compared to integrating vectors. These
vectors are ideal in the treatment of diseases
which require a short therapeutic impact,
such as destroying cancer cells in carcinomas
or delivering vascular growth factors into a
preeclamptic placenta. The vectors derived
from wild-type viruses causing short
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infections usually have transient gene
expression potential, including vectors
derived from e.g. adenoviruses and rarely
used baculo-, herpes simplex, measles and
mumps viruses. Three transient vectors,
adenoviruses, baculoviruses and non-viral
gene vectors are discussed in detail in the
next paragraphs.
Adenoviruses
Adenoviruses were characterized in 1953 and
in humans they are commonly associated
with mild respiratory tract infections.
However, they can infect a wide range of
mammalian cells and many other types of
clinical syndromes, including gastroenteritis,
conjuctivitis and myocarditis, are not rare
(Horwitz, 2001). Wild type viruses are shown
to be oncogenic in rodent cells, but
adenoviral DNA has not been found in
human tumors (Shenk, 2001).
The non-enveloped adenovirus
particle measuring 70-100 nm in diameter
contains a linear, double-stranded DNA
genome 30-35 kb in size in an icosahedral
protein shell (Shenk, 2001). More than 50
different serotypes in six subgroups are typed
inside the adenovirus family. The serotype
Ad5 is widely studied and most often used in
gene therapy. The most commonly used
vectors are replication-incompetent, but
replication-selective adenoviruses are also
used in clinical phase II/III cancer studies
(Reid et al., 2002). These so called oncolytic
adenoviruses have limited capacity to
replicate in certain types of cancer cells,
mediated by genetic modifications in their
genome (promoters and/or deletions).
Replication of the oncolytic adenoviruses
causes cell lysis. (Hedley et al., 2006; Reid et
al., 2002).
Adenoviral vectors are able to
transduce both dividing and non-dividing
cells, and strong but transient gene expression
lasts less than one month (Horwitz, 2001).
Nearly all wild type serotypes, including
serotype Ad5, are internalized into a cell by
binding to a cell surface protein, coxsackie-
adenovirus receptor (CAR), and then by
endocytosis. In the cell the viruses undergo a
stepwise dissociation as they escape the
endosome, and they are transported to the
nuclear area with the help of the microtubular
net of the cell. The transformed viral capsid
docks to the nuclear pore complex and the
uncoated viral DNA is injected into the
nucleus as stripped nucleoprotein (Greber et
al., 1997; Whittaker et al., 2000). After
reaching the nucleus, the transgene is
expressed as episomal DNA (Horwitz, 2001).
However, integration of vector DNA into the
host cell genome in vitro is shown to occur at
least at a frequency of 10-5, but the clones
seem to be only fragments of the vector
genome (Harui et al., 1999; Tsukui et al.,
1996).
The low integration tendency and
efficient transduction capability of both
dividing and non-dividing cells make
adenoviruses potent gene vectors in treating
many kinds of clinical syndromes. These
vectors are already widely used in clinical
trials of gene therapies for cancer and severe
hereditary syndromes (Griesenbach et al.,
2006; Raki et al., 2006). In addition, there are
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quite a lot distribution and safety studies and
the general safety of these vectors has been
found to be good. Fever and mild respiratory
syndromes, and mildly elevated liver
enzymes have been reported after adenoviral
gene therapy (Lozier et al., 2002).
Adenoviruses activate innate
immune responses shortly after
administration in vivo. The trigger which
activates the immune system is the viral
particle or capsid, and not transgene product
(Liu and Muruve, 2003). However, although
virtually all patients have immunoglobulins
against adenoviruses, most of these
antibodies are not neutralizing (Chirmule et
al., 1999; Reid et al., 2002).
After systemic application, anti-
adenovirus antibodies have the capability to
activate the complement system and induce
inflammatory reactions, which may lead to
serious adverse effects in treated patients
(Raper et al., 2003). The severe systemic
inflammatory response triggered by
adenoviral gene therapy of ornithine-
transcarbamylase deficiency which led to the
death of a young patient has highlighted the
importance of accurate pretreatment
evaluation and selection of the patients
(Marshall, 1999). Indeed, as the range of
gene therapy protocols in clinical trials
increases, the safety issues concerning the
immunological reactions after direct
administration of adenoviruses into the
systemic circulation will have to be faced.
(Reid et al., 2002).
Adenoviral distribution studies in the
reproductive organs. Foreign genes have
been successfully introduced into animal
germ line cells in vitro with adenoviral
vectors during early embryogenesis, but there
seems to be generally low integration
frequency and high toxicity. Even after
assisted bypassing of the ZP layer protecting
the oocyte and the early embryo, the
transduction efficiency in oocytes seems to
be poor. The only successful generation of
transgenic animals by adenoviral gene
transfer has been made by Tsukui et al. by
incubating mice zona-free blastocyst stage
embryos in an adenovirus solution (Tsukui et
al., 1996). Afterwards similar, repeated
studies done by other groups with zona-free
oocytes or early stage embryos have neither
led to transgene transmission into the germ
line, nor to the development of transgenic
progeny (Gordon, 2001; Gordon, 2002b). The
injection of viruses into the perivitelline
space of mouse, rat and cow embryos
indicate that efficient transgene expression
does not take place until two-cell stage
embryos (Gordon, 2002b; Kubisch et al.,
1997). Together with the finding of
adenoviruses causing toxicity and
developmental delay in embryos after the 2-
cell stage, a hypothesis was made by Gordon
et al. (2002) that one-cell stage embryos and
oocytes do not possess the features needed
for adenoviral infection (Gordon, 2002a;
Kubisch et al., 1997)
A considerable number of in utero
adenoviral gene therapy studies are available,
but vector distribution data including germ
line alterations are few. Adenoviruses have
been shown to induce an acute, dose-related
toxicity in fetuses leading to intrauterine
death, and seem to have a broad hematogenic
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spread throughout the developing fetus, and
transplacental passage to the maternal
circulation in some conditions (Themis et al.,
1999). However, in germ line studies only
weak signals in PCR analysis of the gonads
have been noted after injections into fetal
heart, muscle, liver, umbilical vein or
intraperitoneal cavity, suggesting poor vector
DNA shedding into gonadal tissues of the
fetus. Additionally, no signs of gene
expression have been noted (David et al.,
2003; Themis et al., 1999).
In vivo studies concerning germ line
effects and risks of vertical transmission
during somatic gene therapy in adult females
are few. In PCR analysis vector DNA has
been found in ovarian tissue after inoculation
of adenoviruses (dose from 108 to 1011
particles/kg) into the peritoneal cavity or
systemic circulation of adult female mice and
rabbits, but the exact localization of the
transgene in the reproductive tissue remains
unresolved (Cichon et al., 1999; He et al.,
2005; Page et al., 2007; Perrotte et al., 2000;
Wood et al., 1999; Ye et al., 1998). In two
more specific studies done with female mice,
neither direct exposure of the ovaries to high
doses of vector through ovarian bursa, nor
systemic injection has led to germ cell
transduction or transgenic progeny in adult
mice (Gordon, 2001; Ye et al., 1998).
Efficient gene expression has been
obtained in other organs of female
reproductive tract excluding the ovaries. In
the mouse uterus CAR is expressed in the
endometrial epithelial cells. In these cells
strong gene expression has been achieved
with intraluminal uterine inoculation of
adenoviruses, regardless of the stage of the
reproductive cycle (Beauparlant et al., 2004;
Kimura et al., 2005; Tang et al., 2005). Also,
in rhesus monkey cervical cells efficient
transduction has been obtained in vivo with
local administration (Hamada et al., 1996;
Mitchell et al., 1996).
Adenoviral shedding into male germ
line cells has been widely studied and the risk
of vertical transmission has been shown to be
quite low. In spermatogonial stem cells CAR
has not been detected but it is present on the
surface of very early spermatids and
spermatozoa of mice, rats and humans (Mirza
et al., 2006). CAR is exposed on the surface
of mature spermatozoa after the acrosome
reaction but the receptor is not accessible in
acrosome-intact germ cells: this indicates a
low possibility of adenoviral entry into
differentiated spermatozoa (Mirza et al.,
2006). Indeed, efficient transduction with
adenovirus vectors has been achieved in vitro
only in spermatogonial stem cells but not in
differentiated spermatids (Blanchard and
Boekelheide, 1997; Hall et al., 2000;
Takehashi et al., 2007). In vivo, even direct
injection of adenoviruses into the testis has
not led to the germ line transmission of a
transgene and no transgenic progeny has been
obtained, even though vector DNA has been
detected from the testis tissue by PCR
analysis (Blanchard and Boekelheide, 1997;
Hall et al., 2000; Hiltunen et al., 2000;
Kanatsu-Shinohara et al., 2002; Kojima et al.,
2003; Kojima et al., 2007; Ni et al., 2005;
Paielli et al., 2000; Peters et al., 2001).
In conclusion, efficient but transient
transgene expression is obtained in ovarian
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and uterine tissues with adenoviral vectors,
but innate immunity and associated toxicity
interfere with their use in vivo. Adenoviruses
seem to exhibit high toxicity during early
embryonic and fetal development. On the
other hand, high and transient gene
expression can be achieved in murine
embryos after the two cell stage. In in vitro
and in vivo studies, efficient transduction of
germ cells has not been achieved by direct
exposure to high doses of adenoviruses,
which suggests that inadvertent vertical
transmission of transgene into offspring
during somatic gene therapy is highly
unlikely.
Baculovirus
Baculoviruses are considered ancient insect
viruses, which have contributed to the
evolution of viruses of higher animals. These
large, 250-300 nm long rod-shaped,
enveloped viruses with diameter of 30-60 nm
have commonly been used as biopesticides in
agriculture (Kost and Condreay, 2002). In
biochemical investigations they have been
used as efficient gene vectors for protein
production in eukaryotic cells because their
large double-stranded circular DNA genome
of 90-160 kb size allows insertion of large
transgenes (Condreay et al., 1999). Two
morphologically distinct forms of infectious
particles are found: one type is an enveloped
virion and the other type, which is used in
gene therapy, is surrounded by a plasma
membrane and is called a budded virus.
Although in nature the wild type
baculoviruses are able to infect mainly
invertebrate species and cannot replicate in
mammalian cells, recombinant baculoviral
vectors can enter mammalian cells. The
interaction of viral envelope glycoprotein
gp64 and phospholipids on the cell
membrane may play an important role in
infection, but the exact virus-cell interactions
and the mammalian receptor for baculovirus
remains unknown (Ghosh et al., 2002; Kost
and Condreay., 2002; Tani et al., 2001; van
Loo et al., 2001). Viruses are able to infect
both dividing and non-dividing cells and the
viral DNA is supposed to be released into the
nucleus through the nuclear pore complex
(van Loo et al., 2001). The viral DNA
products are successfully expressed in vitro
in many types of mammalian cells and the
expression of viral genes is transient lasting
from one day to two weeks after gene transfer
(Ghosh et al., 2002; Kost and Condreay,
2002). However, stable expression and even
integration of baculoviral DNA into the host
cell genome has been reported (Condreay et
al., 1999; Merrihew et al., 2001).
Baculoviral distribution studies in
reproductive organs. High systemic toxicity
and low transduction efficiency caused by
inactivation of the virus by the complement
system has limited the use of baculoviral
vectors in vivo (Hoare et al., 2005; Hofmann
and Strauss, 1998). However, after
inoculation of the modified vectors into target
tissues which are not directly exposed to
serum complement, such as brain tissue, high
transfection rates have been obtained
(Airenne et al., 2000; Haeseleer et al., 2001;
Pieroni et al., 2001; Sarkis et al., 2000). In
addition, the vectors seem to spread from
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these tissues through the lymphatic system
and can reach the common internal organs
(Lehtolainen et al., 2002; Raty et al., 2006;
Raty et al., 2007; Tani et al., 2003).
Systemic application of
baculoviruses has been shown to enhance the
expression of inflammatory cytokines, and
even systemic complement activation leading
to severe shock in mice has been proposed
(Ghosh et al., 2002; Hoare et al., 2005).
Attempts to bypass the complement reaction
by inserting regulating molecules into the
viral envelope have been shown to work in
vitro but in vivo studies with these
modifications cannot be found in the
literature (Hofmann and Strauss, 1998; Huser
et al., 2001).
No vector distribution data on the
baculoviral shedding into female
reproductive organs is available, but effects
of intratestical and fetal administration have
been studied. After direct exposure of the
testis to baculoviral vectors no staining was
noted in germ cells, although other cell types
were efficiently expressing the transgene
(Tani et al., 2003). The sperm of treated
animals was not studied and the distribution
of vector DNA into germ cells remains
unstudied. In mouse embryos, high toxicity
was noted after intravenous baculovirus
administration, causing autolysis and rapid
abortion of all treated fetuses (Hoare et al.,
2005).
In conclusion, baculoviral gene
vectors efficiently transduce many dividing
and non-dividing mammalian cell types in
vitro, but in vivo their use is limited by
toxicity and tendency to be inactivated by the
complement. However, in complement-
deprived environment efficient baculoviral
transgene transmission has been obtained in
vivo, including efficient transgene expression
in testis tissue. The effects and distribution of
baculoviral gene therapy in reproductive
organs and germ cells are studied to some
extent in males but not at all in females.
Non-viral vectors
In gene therapy foreign DNA has been
introduced into the target tissues by many
non-viral methods in addition to the use of
natural viral vehicles. The first report of the
utilization of synthetic cationic lipids as gene
carriers was made by Felgner et al. at 1987
(Felgner et al., 1987). From the large
spectrum of molecules currently used as non-
viral DNA vehicles, four subgroups can be
distinguished: forms of naked DNA, cationic
lipid complexes, polypeptides and polymers
(Niidome and Huang, 2002).
The immunogenicity of non-viral
vectors is very low, but high toxicity has been
observed with certain cationic lipids and
polymers. This restricts their use in vivo and
especially slows down their entry into clinical
trials (Lv et al., 2006). In normal conditions
the non-viral vectors are not able to pass
through the endothelial barrier of the vascular
system, and they are shown to degrade
rapidly in circulation. In contrast, under
patholocical conditions, e.g. during tumour
formation or inflammation, the vascular
leakage of small particles increases and
complexes smaller than 100 nm are able to
extravasate and elicit a wide spread via the
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lymphatic drainage after local injection
(Ulrich, 2002).
In theory, the DNA complexes 100-
450 nm in size are thought to be taken up into
the host cells by lipid fusion to the plasma
membrane, but it has been shown that
particles smaller than 150 nm can be
internalized by endocytosis and bigger
particles by phagosytosis (Ulrich, 2002).
When reaching the nucleus, the expression of
episomally located transgene is transient and
has a very low tendency to integrate.
However, with modified vectors
incorporating components of transposons,
which are naturally capable of moving from
one chromosomal location to another,
integration into the host cell genome has been
obtained in non-dividing cells in vivo in mice
(Yant et al., 2000).
Distribution of naked DNA in reproductive
organs. Naked DNA seems to spread
throughout the body shortly after the gene
transfer regardless of the administration
route. However, the vector is flushed out
from the organs in hours, or at least in the
first few days, leading to the absence of
transfection in the tissues. Transgene DNA
has been noted in reproductive tissues shortly
after local administration of large doses of
naked plasmids intradermally or
intratumorally, but the positive signals have
diminished after a few days (Hengge et al.,
2001; Imboden et al., 2003; Parker et al.,
1999; Tuomela et al., 2005; Walther et al.,
2006). Only in pig ovaries, after a large
intradermal dose, has RNA production been
noted during the first days after gene transfer,
but no positive southern blotting results were
obtained suggesting episomal expression
(Hengge et al., 2001).
Naked DNA is poorly internalized
into the cell and methods for enhancing the
transduction by weakening or totally
bypassing the limiting factors, such as the
cell membrane, have been introduced. These
techniques include electroporation and
microbubble ultrasound, which unstabilize
the cell membrane. Pronuclear injection and
freezing can also be used to bypass or
weaken the cell membranes. With pronuclear
injection of naked DNA in singular plasmid
form into mice eggs stable expression has
been observed in newborn animals and even
transgenic F1 progeny have been obtained
with a pronuclear injection of artificial
chromosome (Co et al., 2000; Gordon et al.,
1980). Also, spontaneous uptake of plasmid
DNA by frozen-thawed bull spermatozoa was
nearly double the transfection rate of fresh
ones, which indicates that the
cryopreservation-induced changes in the
plasma membrane facilitate the DNA
internalization into the spermatozoa (Anzar
and Buhr, 2006).
With direct injection of naked
plasmid into mice testes combined with
electroporation, a long lasting transgene
expression in all testicular cell types,
including germ cells, has been observed.
However, no transgenic progeny have been
obtained (Umemoto et al., 2005; Yamazaki et
al., 1998). Also, in vitro integration of
transgene into spermatozytes has been
enhanced by the use of restriction enzymes,
which cut the cell DNA, favoring the
integration of plasmid DNA into the cell
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genome (Shemesh et al., 2000). Without any
transduction enhancing methods ambivalent
results concerning the uptake of exogenous
DNA into spermatozoa has been reported, the
transfection rates varying from fairly high to
non-existent, and the factors leading to these
disconcerting results remain unknown
(Huguet and Esponda, 1998; Maione et al.,
1998).
Vertical transmission data after in
utero gene transfer, IUGT, with naked DNA
is controversial, as some stable transfection
has been reported among many transient
results. In rats during late pregnancy, vertical
transmission via testicular tissue was reported
by Gallot et al. after in utero intraperitoneal
(i.p.) administration of plasmid modified with
simian virus DNA (Gallot et al., 2002).
However, in mice naked DNA injection into
various fetal cavities, combined with the
microbubble-ultrasound method, has not led
to stable transduction, although transient
transgene expression has been noted in
gonadal tissues up to one week from gene
transfer (Endoh et al., 2002).
Distribution of cationic lipid and polymer
complexes. Efficient but transient transgene
expression has been obtained in vitro with
cationic compound mediated gene transfer in
zona-free oocytes and embryos, and in
spermatozytes with low risk of integration
into the germ line genome (Bachiller et al.,
1991; Carballada et al., 2000; Yonezawa et
al., 2001). In male mice, pigs and rabbits
inadvertent distribution of lipid/DNA
compounds into the reproductive tissues and
germ line cells in vivo has occurred rarely
after systemic administration (Nabel et al.,
1992; Ochiya et al., 1999). However, after
direct intratestical inoculation of lipid
compounds with or without electroporation,
transgene positive spermatozoa have been
observed shortly after gene transfer with a
low germ line integration tendency (Sato et
al., 2002; Yonezawa et al., 2001).
The distribution of cationic
complexes in female reproductive tissues has
been studied in pregnant and non-pregnant
animals, and the overall results indicate a
very low risk of vertical transmission both
during fetal time and throughout the female
lifespan. However, shortly after systemic or
local cationic vehicle administration the
distribution of transgenes into ovaries has
been shown to occur in mice, but no signs of
germ line transfection has been observed
despite widespread transgene expression
(McLachlan et al., 1995; Nabel et al., 1992;
Niven et al., 1998; Ochiya et al., 1999; Oh et
al., 2001; Thierry et al., 1995; Xing et al.,
1998; Zhu et al., 1993). In pseudopregnant
mice endometrial epithelium and oviductal
cells have been successfully transfected with
an intraluminal inoculation of
plasmid/liposomes (Relloso and Esponda,
1998; Relloso and Esponda, 2000).
Moreover, intact human uterine tissues, from
endometrial cells to myometrium, have been
efficiently transfected with an intraluminal
uterine inoculation of DNA/liposomes
(Daftary and Taylor, 2001).
The ability to pass through the
placental barrier depends on the
characteristics of the vector and
transplacental transmission of the transgene
has been noted in rodents and rabbits after
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maternal systemic administration with certain
lipid and polymer compounds (Heikkila et
al., 2001; Kikuchi et al., 2002; Ochiya et al.,
1999; Okuda et al., 2001; Tsukamoto et al.,
1995). In addition, before implantation only
small amounts of DNA can be found in the
mouse embryos after systemic administration
into the mother in contrast to the efficient
transfection noted in postimplantation
embryos (Kikuchi et al., 2002; Tsukamoto et
al., 1995). The intraluminal uterine gene
transfer has not disrupted later pregnancies in
mice and normal young have been born
(Charnock-Jones et al., 1997).
The suitability of a non-viral gene
vector for in utero gene therapy depends on
the liposome compound. Toxic effects in
mouse fetuses have been noted with certain
cationic lipids, whereas efficient but transient
fetal transfection has been obtained with
others, including the spreading of transgene
DNA into fetal reproductive organs (Gaensler
et al., 1999; Gharwan et al., 2003; Kikuchi et
al., 2002). However, the absence of
detectable plasmid DNA in fetal mouse
gonadal tissue four weeks after injection
suggests that the germ line cells are unlikely
to be stably transfected (Gaensler et al.,
1999).
In conclusion, non-viral gene
transfer vehicles can efficiently and
transiently transfect female reproductive
tissues during fetal time and throughout the
female life span. However, the transfection
pattern, toxicity and transfection efficiency
vary between different lipid compounds.
Spreading into ovarian and testicular tissues
frequently occurs shortly after in vivo
administration, but germ line integration is
highly unlikely and no transgenic progeny
has been obtained even with the use of
transfection enhancing methods in vivo. The
limiting factors of in vivo use of non-viral
vectors are the rapid degradation in blood and
the toxicity of specific polymer compounds.
Vectors for stable gene expression
Integrating gene vectors are ideal tools for
correcting clinical syndromes in which a life-
long therapeutic effect is needed, but their
use in antiangiogenic cancer gene therapy has
also been studied (Ramakrishnan et al.,
2005). Additionally, these vectors offer a
great tool for treating hereditary syndromes
with in utero gene therapy. Some natural
viruses, such as retro-, lenti- and adeno-
associated (AAV) viruses have an ability to
integrate their genome into host cell genomes
and cause chronic infections. Gene vectors
derived from these viruses are used in gene
therapy for inducing stable, life-long
therapeutic effects. The most commonly used
integrating viral vectors are murine leukemia
virus (MuLV) from the retroviridae group,
human immuno deficiency virus (HIV) from
the lentiviridae group, and AAV, and these
are discussed in detail in the next paragraphs.
Retro- and lentiviruses
Retroviruses are a complex family causing a
wide range of syndromes varying from
benign to fatal diseases such as AIDS. They
exhibit a tendency to integrate into the host
cell genome and therefore are oncogenic
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viruses inducing chronic infections. The
history of the identification of the infections
caused by these viruses goes back to the
beginning of 20th century but even though the
complex infection mechanism has been
widely studied, it is still not thoroughly
understood (Desrosiers, 2001). Human
lentiviruses, HIVs, were first noticed in 1981
when young adults were killed by an
unknown immunologic dysfunction. The
same kinds of immuno-deficiency viruses are
found among other species and the infection
is fatal. HIV is mainly transmitted through
mucosal and blood contact and by breast
feeding, and the genetic evolution of these
viruses is rapid (Freed and Martin, 2001).
The viruses belonging to the
retroviridae family are rather large,
enveloped spherical viral particles reaching a
diameter of 100 nm. Inside the lipid bilayer is
a proviral protein shell in which are located
two copies of linear, single-stranded RNA 7-
11 kb in size, and functional enzymes needed
for viral action. Inside the retroviridae family
both simplex and complex viral structures
can be found and viruses from both these
classifications are utilized in gene therapy.
From these, modified gene transfer vectors
based on MuLVs from the simplex retrovirus
family, and HIV from complex lentivirus
family are the most commonly used in gene
therapy trials. The simplex retroviruses are
unable to pass through the nuclear membrane
and can only infect dividing cells, but the
complex lentiviruses have the machinery for
nuclear penetration (Goff, 2001).
The series of events in retroviral
infection involve many steps (Whittaker et
al., 2000). In interaction with the cell surface
the MuLVs can use many receptors. In
contrast, wild type human lentiviruses enter
the cell by first binding to a CD4 cell surface
receptor, which is mostly found in
immunologic cells such as CD4+ T-helper
cells. With the help of co-receptors the viral
membrane is brought together with the cell
membrane and the virion enters the cell by
membrane fusion. However, the recombinant
lentiviral gene vectors seem to use various
receptors in cell penetration. In vector
pseudotyping vesicular stomatitis virus G-
protein (VSV-G) is commonly used as an
envelope protein on the viral surface (Miller,
1996). In cytoplasm the viral reverse
transcriptase encodes viral RNA into DNA,
which is transported through cytosol using
cellular microtubules (Goff, 2001). In the
transport of the DNA into the nucleus
through nuclear pores both viral proteins and
receptors in the nuclear envelope seem to be
used, and with help of integrase the viral
DNA is permanently incorporated into the
host cell genome (Goff, 2001; Whittaker et
al., 2000).
Retro- and lentiviral distribution studies
and the risk of vertical transmission. Both
retro- and lentiviruses have successfully been
used in developing transgenic mice by
transducing germ line cells and early stage
embryos in vitro. In recent studies the wild
type lentiviruses’ DNA has been noted in
follicular fluid but not directly from oocytes,
which suggests that the virus has the ability
to penetrate the follicular basement
membrane (Ali Al Ahmad et al., 2005;
Bertrand et al., 2004; Cortez Romero et al.,
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2006). Additionally, HIV DNA has been
found in human spermatozytes of infected
males (Baccetti et al., 1994). In contrast, in
male goats infected by goat lentivirus, the
caprine arthritis encephalitis virus, the
spermatozoa fraction did not contain
lentiviral DNA, although the semen was PCR
positive (Ali Al Ahmad et al., 2008).
Injection of lentiviral gene vectors
into the perivitelline space around oocyte or
incubation of naked oocytes in retroviral
solution in vitro have both resulted in the
development of transgenic animals in mouse
and non-human primate models (Chan et al.,
2001; Lois et al., 2002). In addition, stable
germ line transduction leading to transgenic
progeny has been achieved with in vitro
incubation of zona-free early-stage mice
embryos with MuLVs (Jaenisch, 1976; van
der Putten et al., 1985). However, the
transgenes of onco-retroviruses are
developmentally silenced in contrast to
lentiviral ones, which has been shown to
display a stable tissue-specific expression
when tissue-specific promoters are used
(Ikawa et al., 2003; Lois et al., 2002). A
disadvantage in the use of retroviruses in the
production of transgenic animals is random
integration into germ line genome, which
may lead to vector-associated tumorigenesis
and even result in recessive lethal mutations
(Soriano et al., 1987; Themis et al., 2005).
Retroviral gene transfers made into
hematopoietic stem cells ex vivo has resulted
in an increased occurrence of leukemia
among both murine and large animal models
(Li et al., 2002; Zhang et al., 2008). In
addition, in the treatment of lethal Severe
Combined Immuno-Deficiency syndrome,
SCID-X1, with ex vivo gene transfer into
CD34+ cells, insertional mutagenesis has
resulted in leukemia and the death of one
patient out of twenty patients in phase II/III
studies (Cavazzana-Calvo and Fischer, 2007).
In in utero gene therapy the
retroviruses are promising tools with their
characteristic stable transgene expression,
and they are widely studied in the fetuses of
many laboratory animals. In a study with
wild-type HIV in humans indications of
vertical transmission from infected mother to
developing baby during pregnancy have been
reported: in a study with HIV seropositive
Ghanaian women 13 cord blood samples
from total 97 (13.5%) contained HIV RNA
(Fischetti et al., 2005). However, in non-
human primates the amniotic fluid seems to
inhibit retroviral infection but direct vector
administration into the fetus leads to high
transduction efficiency with low immediate
toxicity (Bennett et al., 2001).
With direct i.p. inoculation of
retroviruses into sheep fetuses (Porada et al.,
2005; Tran et al., 2000), VSV-G pseudotyped
HIV into nun-human primate fetuses
(Jimenez et al., 2005; Lee et al., 2005) or
direct i.v. inoculation of VSV-G preudotyped
eguine infectious anemia virus into mouse
fetuses (Waddington et al., 2003) the vector
DNA has been observed in gonadal tissues of
both genders and even in extracted oocytes.
However, no transgenic progeny from the
treated animals has been obtained. Instead,
after i.p. inoculation of MuLV into mice
neonates, up to 8 % of the young born from
the transgenic grown-up females were
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positive for provirus, indicating stable germ
line integration (Panthier et al., 1989).
In adult animals the viral distribution into
reproductive organs occurs but the risk of
vertical transmission seems to be low,
although there are very few studies
concerning the female germ line. In females
the viruses seem to be blocked outside the
follicles, or may not even reach them
(Panthier et al., 1989; Peng et al., 2001).
Moreover, pseudotyping and vector targeting
into specified tissues has been shown to
reduce the inadvertent germ line distribution
of HIV vectors (Peng et al., 2001). However,
studies with direct exposure of ovaries to
large dose retroviral gene therapy cannot be
found in the literature.
Transplantation of male germ line
stem cells transduced in vitro with MuLV and
HIV, into recipient testis has led to high
transduction efficiency in germ cells and
stabile germ line integration leading to
transgenic progeny (Hamra et al., 2002;
Nagano et al., 2000; Nagano et al., 2001;
Nagano et al., 2002). On the contrary, in vivo
the retroviral transduction efficiencies in
spermatozytes has been very low; the highest
rate being one per 714 sperm cells, which
was obtained with direct inoculation of
MuLVs into seminiferous tubules in mice
(Nagano et al., 2000; Roehl et al., 2000).
After gene transfer in vivo into adult male
animals with retroviral vectors no results of
vertical transmission of transgene into
progeny has been reported.
In conclusion, retroviruses are
potent gene therapy vectors at least in in vitro
and in utero gene therapy protocols.
However, the relatively high risk of germ line
transmission, oncogenicity and
developmental silencing are disadvantages
limiting their therapeutic use. The natural
pathology of lentiviruses and the complex
infection mechanism with rapid tendency of
viral genome evolution raises the concern of
adverse effects in clinical applications.
Adeno Associated Viruses
Adeno associated viruses, AAVs, were first
noted in the mid-1960s and since then at least
eight true serotypes and over hundred
variants of these small members of the
Parvoviridae family have been classified (Wu
et al., 2006). AAVs are small, non-enveloped
DNA-viruses containing single-stranded
DNA, approximately 5 kb in size in a single
icosahedral nucleocapsid with a diameter of
only 18-26 nm (Muzyczka and Berns, 2001).
AAVs can infect many invertebrate and
vertebrate cell lines, and both dividing and
non-dividing cells. Each serotype has its own
tissue preference, but naturally none of them
seem to have a high tendency to infect
gonadal tissue (Mori et al., 2008). However,
without co-infection of another virus, the
wild type AAVs are non-pathogenic and are
not known to cause any specific clinical
infection. Instead, the virus integrates into the
host cell genome in dividing cells or may stay
episomally in non-dividing cells from weeks
to years (Bloom and Young., 2001; Russell et
al., 1994).
Vectors derived from multiple AAV
serotypes are used in gene therapy. Wild type
AAVs expressing Rep-protein integrate into
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chromosome 19, but the replication-defective
AAV recombinants used in gene therapy lack
this coding sequence and seem to integrate
randomly without any specific integration site
in the cell genome (Flotte and Carter, 1995).
In cell penetration AAVs may use many cell
surface proteins as receptors and enter the
cell via endosomes. In the cytocol, these
viruses use the microtubules for transport,
and they are potentially small enough to pass
through the nuclear pore complex. However,
the exact mechanism for viral entry into the
nucleus is as yet unknown (Bloom and
Young, 2001; Whittaker et al., 2000).
Nearly all humans have natural
antibodies and memory T-cells against AAV
antigens and the humoral responses may
cause problems in AAV mediated gene
therapy.  However, most of these antibodies
do not seem to be neutralizing and do not
prevent the efficacy of vector
readministration (Chirmule et al., 1999;
Chirmule et al., 2000; Jerebtsova et al.,
2002).  In clinical trials, transgene expression
is shown to begin to decline from 4 to 6
weeks after the gene transfer, and this is
thought to be caused by rejection of
transduced cells by AAV capsid-specific
memory CD8+ T-cells (Mingozzi et al.,
2007). In in utero gene therapy, the AAV-
specific IgG in amniotic fluid strongly
inhibits the transduction efficiency if intra-
amniotic routes are used (Boyle et al., 2003).
Distribution studies in reproductive organs
and risk of vertical transmission. AAVs are
already in use in phase I and II clinical trials
in treating chronic hereditary syndromes and
positive results have been reported. Patients
suffering severe haemophilia have been
treated by intramuscular (i.m.) and intra-
arterial AAV injections (Manno et al., 2003;
Manno et al., 2006). Therapeutically relevant
levels of transgene product, Factor IX in
severe haemophilia, were obtained but the
expression was limited to a period of 8 weeks
(Manno et al., 2006). Patients having cystic
fibrosis have been treated with instillation of
AAV into the maxillary sinus (Wagner et al.,
2002). After i.m. administration of AAV in
haemophilic males no vector DNA has been
detected in semen samples taken during the
first post-operative week. However, after
direct administration of AAV into the hepatic
artery, the vector sequence has been noted
once from purified motile sperm, raising the
possibility of germ line transduction (Manno
et al., 2006).
The integrative character of AAVs
has made them promising tools for in utero
gene therapy but fetal toxicity of the virus
should be noted. In vitro AAV2 infection
tends to arrest the development of fertilized
mouse eggs, and in vivo the infection of
pregnant female with wild type AAVs and
AAV2-based gene vectors has been reported
to disturb placental and early embryonal
development leading to an elevated rate of
early miscarriage in humans (Botquin et al.,
1994; Burguete et al., 1999; Tobiasch et al.,
1994). In later pregnancy direct AAV
injections through various routes into the
fetuses of laboratory animals have not led to
elevated abortion rates.
The distribution studies of AAV
vectors in fetuses have shown the risk of
vertical transmission to be very low, although
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vector dissemination into gonads may occur.
After intrahepatic inoculation in fetal rhesus
monkeys, and i.v. and i.p. administration of
AAV2 into prenatal and newborn mice, the
vector sequence has been detected in a small
percentage of gonads, persisting through the
one year follow-up in mice (Jakob et al.,
2005; Lai et al., 2002). In contrast to the
findings with AAV2, with intrauterine i.p.
injection of AAV5 into mouse fetuses all
gonadal samples were found positive for
vector sequence in PCR analysis (Lipshutz et
al., 2003). In spite of the positive PCR results
from the reproductive tissue itself, no
evidence of germ line transmission in in situ
hybridization was noted and the vector DNA
was found neither from isolated sperm nor
from the offspring of the in utero AAV2
treated mice (Jakob et al., 2005; Lipshutz et
al., 2001).
In adult animals, numerous studies
covering AAV dissemination into semen and
male gonads can be found but the number of
studies concerning female germ cells are
limited. In the parallel results of male in vitro
and in vivo studies, the rate of germ line
integration has been found to be very low,
although dissemination of AAV into gonadal
tissue and semen frequently occur in many
laboratory species including non-human
primates (Arruda et al., 2001; Conrad et al.,
1996; Couto et al., 2004; Flotte et al., 2007;
Nathwani et al., 2007; Pachori et al., 2004;
Schuettrumpf et al., 2006). However, an
increased incidence of AAV infection with
abnormal semen analysis in infertile males
may indicate increased elimination of
infected sperm from semen predisposed to
AAV, at least in humans (Erles et al., 2001).
Indeed, the only method for achieving
transgenic progeny with AAV has been in
vitro exposure of undifferentiated mouse
male germ cells to gene vectors and
transplantation of these to recipient animal
testes (Honaramooz et al., 2008).
In AAV dissemination studies in
female adults the possibility of vertical
transmission has not been studied. However,
after i.v. and i.p. administration of AAVs into
non-human primates, mice and rabbits the
vector sequences have been observed in
gonadal tissue with PCR. The number of
positive results decreased over time (Flotte et
al., 2007; Isayeva et al., 2007; Mori et al.,
2006). In vitro, the ZP surrounding the
mature mouse oocytes seems to block the
AAV particles and inhibit the infection
(Couto et al., 2004).
In conclusion, AAVs with their
integrative tendency and the ability to
transduce many kinds of dividing and non-
dividing cells are potent gene vectors for
treating chronic disorders. However, low
transduction rate and immunogenicity restrict
their use in vivo. AAVs have the ability to
transduce the gonadal tissues throughout the
life but the risk of vertical transmission is
low. Transgenic progeny has been achieved
only after in vitro transduction of
undifferentiated mouse male germ cells but in
vivo the humoral responses together with the
toxicity of AAV in early embryos make the
possibility of the vertical transmission very
improbable. However, vector distribution
studies made with females are insufficient to
make definitive safety deductions.
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Table 1: Characteristics of certain viral gene vectors.
Characteristics Transduction ability
Adenovirus Non-enveloped, diameter 70-100 µm
Genome: double stranded DNA
>30 kb transgene capacity
Transduce dividing and quiescent cells
Non-integrating, transient gene expression
Pathogenic, high immunogenicity
Fetal toxicity during early developmental
stage
Broad tropism in vitro and in vivo
Zona-free, fertilized oocytes in vitro
Uterine and ovarian tissues in vivo
Sperm in vitro and in vivo
Fetal gonad in IUGT
No vertical transmission
Baculovirus Enveloped, length 250-300 µm
Genome: double stranded DNA
High transgene capacity
Transduce dividing and quiescent cells
Non-integrating, transient gene expression
Non-pathogenic, destroyed by complement
Fetal toxicity
Broad tropism in vitro
In vivo low distribution:
  Complement-deprived tissues
Testis tissue in vivo, not in germ
cells
No vertical transmission?
Nonviral DNA in 100-450 µm liposome or polymer
shell
High transgene capacity
Non-integrating, transient gene expression
Rapidly destroyed by immune system
Transfect dividing and quiescent cells
Fetal toxicity with certain polymers
Low cellular intake
Zona-free, fertilized oocytes in vitro
and sperm in vitro
Uterine and ovarian tissues in vivo
All testicular cell types with
electroporation in vivo
Transplacentally into fetal gonads
Fetal gonad in IUGT
No vertical transmission*
Retrovirus (MuLV) Non-enveloped, diameter 100 µm
Genome: single stranded RNA
< 10 kb transgene capacity
Transduce only dividing cells
Stable integration and gene expression
Pathogenic, low immunogenicity
Low fetal toxicity
Only dividing cells
Zona-free, fertilized oocytes in vitro
Sperm in vivo and in vitro
Vertical transmission in vitro
No vertical transmission in vivo in
adults
Vertical transmission in IUGT
Lentivirus (HIV) Enveloped, diameter 100 µm
Genome: single stranded RNA
?8 kb transgene capacity
Transduce dividing and quiescent cells
Stable integration and gene expression
Pathogenic, low immunogenicity
Low fetal toxicity
CD4+ cells in vitro and in vivo**
Zona-free, fertilized oocytes in vitro
Sperm in vitro
Fetal gonad in IUGT
Vertical transmission in vitro
No vertical transmission in vivo
AAV Non-enveloped, diameter 18-26 µm
Genome: single stranded DNA
< 5 kb transgene capacity
Transduce dividing and quiescent cells
Stable integration and gene expression
Non-pathogenic, low immunogenicity
Fetal toxicity (wild type viruses)
Broad tropism in vitro and in vivo
Spermatogonial stem cells in vitro
Ovary in vivo
Testis tissue and semen in vivo
Fetal gonad in IUGT
No vertical transmission in vivo
* Vertical transmission obtained with pronuclear injection of artificial chromosome
** Wild-type HIV uses CD4 receptor, but pseudotyped viruses can use wider range of receptors.
Copyright © 2008 Anniina Laurema. All rights reserved.
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Commonly used transgenes in gene
therapy research
In gene therapy the diseases may be managed
by two methods: by replacing a mutated
defective gene or by silencing a detrimental
one. Before being able to treat diseases by
gene therapy, the precise genetic mechanism
of the disease should be known. Additionally,
the basic elements of gene transfer
mechanisms, such as the gene vector
behavior in organisms, should be under strict
control. In basic research the marker genes,
with which the expressed gene product may
be indicated by specific analytical methods,
are used to demonstrate the transduction
efficiency in different target tissues and the
differences between the vectors. One of the
most common marker gene constructs is E.
Coli ?-galactosidase, LacZ, which converts
galactosidase into blue colour and transduced
cells can easily be observed from histological
sections (Kalnins et al., 1983).
In the gene constructs used in gene
therapy the transgene coding region is only a
part of the vector genome and many DNA
elements influencing the gene expression are
combined in the definitive expression cassette
(Waehler et al., 2007). The target area of
transgene can be modified by targeting codes;
for example, the nuclear targeting sequence
causes the transgene product to enter the
nucleus. With tissue specific promoter
sequences the cell type, in which the gene
product is expressed, can be defined. Some
common and potent promoters operating in a
large variety of mammalian cells can also be
found, for example cytomegalovirus (CMV)
and chicken beta actin (CAG) promoters.
Moreover, gene expression enhancer and
regulatory elements, enhancing and
modifying the gene expression, can be
combined into the vector genome and these
characteristics are used in developing
regulated gene vectors (Waehler et al., 2007).
In cancer gene therapy many types
of treatment methods can be used: the
defective gene coding the cell cycle
restriction protein can be replaced by a
functional one; the life-perpetuating
characteristics of the cancer cell environment
can be changed to unviable, for example by
preventing the proliferation of blood vessels
into the tumor; autoimmunization of the
individuals own immune cells to cancer cell
antigens can be provoked by therapeutic
methods;  the cancer cells can be destroyed
by oncolytic adenoviruses or by transfer of a
suicide gene into dividing cells (Runnebaum,
1997).
One of the suicide genes used in
cancer gene therapy is the herpes simplex
virus thymidine kinase (HSV-TK) which
converts ganciclovir into its active
metabolite. This metabolite is cytotoxic in
dividing cells and it prohibits DNA
replication by acting as a DNA polymerase
inhibitor and chain terminator leading to the
death of the cell (Ishii-Morita et al., 1997).
The intact cells lining the transduced ones
may also be damaged by the ‘bystander
effect’ which is supposed to derive from the
spreading of the toxic metabolite of
ganciclovir into non-transduced cells through
the cell-to-cell connections (van Dillen et al.,
2002).
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Animal models and methods in vector
distribution studies
In evaluating the safety of gene transfer
agents the following should be taken into
account: the vector modification, the choice
of a relevant animal model, the
administration route, the vector dose, and the
analysis methods of the samples. Vector
pseudotyping may dramatically change the
tissue specificity, toxicity and behavior of the
vectors in animal models (Raty et al., 2008).
Generally, the vectors used in gene therapy
are originally species-specific viruses and
during viral evolution they have adapted their
surface antigens and genome functions for
the receptor repertoire and cell biology of the
target species. Therefore, safety assessment
of gene transfer products should be custom-
designed for each compound. For example,
adenoviruses are not related to human tumor
formation, but their oncogenicity in rodents
has been noted (Shenk, 2001).
The selection of the relevant animal
model for preclinical safety studies is crucial
(Verdier and Descotes, 1999). Mouse and rat
strains are currently the most commonly used
animal models in vector distribution and
reproductive toxicology studies. They are
easy to breed and high study group numbers
with multilevel generations can be achieved
within a short time span. However, the simple
conversion of the safety data obtained from
these animal models into clinical use is
highly doubtful, because the similarity of the
cellular kinetics and immunological
properties between humans and animal
models are not fully understood (Christ,
2002). For example, CD4 antigen, the cell
surface receptor for HIV, is expressed on
mouse spermatozoa, but it has never been
detected on the surface of human
spermatozoa (Dejucq and Jegou, 2001). Also,
the size of the target organ affects the clinical
outcome, as the vector injection locally into
human organs is affecting only a tiny area of
the tissue compared to the effects of local
injection into mouse organs.
The safety study design, including
administration route, should be adapted to the
intended treatment design. In addition, “the
worst-case scenario” should be noted, on the
off-chance that the local high-dose
inoculation of transgene could accidentally be
released into the systemic circulation.  The
anatomical differences between the animal
model used and humans should be pointed
out, such as the circulation of the
reproductive organs and fetal development in
reproductive toxicity studies (Brennan et al.,
2004). For example, the molecular details of
Zona Pellucida, the placental structure and
fetal membrane anatomy differ radically
between species.
The advancing laboratory techniques
play a major role in studying the gonadal
vector distribution at cellular level. The
mature male germ cells are relatively easy to
reach and purify from the ejaculate, but
female germ cells are not obtainable with
such a method. One cellular level method of
analysis of the female germ cells is laser
capture microdissection, LCM, with which
oocytes can be isolated for further studies by
cutting them off from histological sections.
However, a low amount of DNA or RNA is
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obtained from the isolated oocytes and the
complex laboratory practice increases the risk
of contamination.
The selection of a suitable method
for analyzing the distribution is complex and
Gonin suggests quantitative PCR (qPCR) to
be the most accurate method today (Gonin
and Gaillard, 2004). Other analytical
methods, e.g. the histological stainings based
on functioning transgenes or antibodies are
specific, but insensitive methods for
evaluating the distribution. The DNA PCR,
on the contrary is a very sensitive method for
detecting vector DNA in tissues, but the risks
of contamination and false positive results are
significant. Reverse transcriptase PCR (rt-
PCR) in turn shows the transcription of the
transgene and with qPCR the transcriptional
activity can be also measured: but in
metabolically inactive cells, such as resting
oocytes with low level transcription, the RNA
concentration may be very low. The methods
for studying the localization of the transgene
DNA or transcripted, but not expressed,
transgene distribution in specific tissue, LCM
and in situ-hybridization are complicated and
laborious techniques which are insensitive
and have a high risk of contamination. The
method for revealing the transgene
integration and vertical transmission is
Southern Blotting, which is also an
insensitive laboratory technique with low
DNA amounts.
In conclusion, validated analytical
methods and relevant animal models are a
prerequisite for reliable preclinical safety
evaluation. Non-human primates exhibit the
closest similarity with human physiology and
would be the best, but most expensive,
animal models for distribution studies both in
reproductive toxicology and in in utero gene
therapy. The distribution data obtained from
lower animal models serve as rudimentary
data for understanding the basic mechanisms
for the interaction of viruses and the animal
cell.
Factors protecting the oocyte genome
from vertical transmission
The oocyte is a challenging target for gene
delivery, both in studies focusing on the risk
of inadvertent vertical transmission and in
attempts to develop transgenic animals by
germ line transduction. Concerning the risk
of inadvertent germ line effects, germ cells
may be exposed to viruses both in vitro
during in vitro fertilization (IVF) therapies
and in vivo through the exposure of
reproductive organs to gene therapy agents.
In vitro the natural protective elements
surrounding the oocyte are removed and the
gene vector comes into direct contact with the
oocyte itself. However, in attempts to
develop transgenic animals by IVF, even with
the straight injection of gene vectors into the
ooplasm, only a poor integration rate has
been obtained and both oncogenesis and poor
embryo development have been observed
(Chan et al., 2001; Gordon et al., 1980;
Gordon, 2001; Gordon, 2002a; Jaenisch,
1976; Tsukui et al., 1996). Still, it should be
noted that the numbers of oocytes used in in
vitro studies are small and only maturated
oocytes can be used, whereas in ovaries a
pool of thousands of primordial oocytes is
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exposed to the effects of gene therapy in a
single animal. Additionally, virus-like
elements are found in the genomic DNA of
animal cells, which indicates that viral
integration into the germ line occurs at some
stage of reproduction (Hughes and Coffin,
2005).
In vivo intergenerational gene vector
shedding may occur by various mechanisms
during the female reproductive cycle and
pregnancy. The possible mechanisms include
1) the transduction of the oocyte itself, 2) the
vector penetration into the oocyte during or
shortly after fertilization from it’s
surroundings 3) or via binding on the sperm
surface, 4) shedding through fetal
membranes, 5) or through the placenta from
the maternal endometrium during the
decidual reaction of trophoblasts, 6) or
transplacentally from the maternal
circulation.
In the female gonad the gene vector
has to overcome multiple barriers before
reaching the oocyte nucleus. Firstly,
depending on the administration route, it has
to avoid becoming inactivated by the immune
system. Secondly, it has to penetrate into the
ovarian tissue and reach the ovarian cortex.
Thirdly, it has to bypass the follicular
basement membrane to reach the oocyte
surface (Rodgers et al., 1999). Additionally,
in growing follicles the vector has to traverse
through the granulosa cell layer and then the
ZP before reaching the perivitelline space and
the oocyte surface. Finally, it has to penetrate
into the egg cell and manage to transport it’s
genome into the nucleus through the ooplasm
and nuclear pores (Fig. 6). It should be noted
that cytoplasmic projections between
granulosa cells and oocytes reach a diameter
of 50-150 nm and as the diameter of viral
vectors is 100 nm the viral escape from
transduced granulosa cells into oocytes is
theoretically possible (Vanroose et al., 2000).
During fertilization a rapid
activation of the fertilized oocyte takes place.
The spermatocytes traverse through the zona
pellucida and fuse with the egg cells: These
spermatocytes carry surface receptors, on
which viral vectors may bind and penetrate
through the zona with the sperm (Mirza et al.,
2006). Moreover, vectors located in the
perivitelline space may have a change to
enter into the fertilized egg as is starts to
divide.
During pregnancy the fetus is in
contact with the maternal environment
through the uterine lumen and uterine
circulation. Vector leakage from the uterine
lumen into the embryo through the fetal
membranes during early pregnancy may
endanger the primordial germ cells to
transgene effects, as the cells are migrating
from more superficial exocoelomic cavity
into the developing reproductive organs.
Also, during the early development of the
placenta the trophoplastic cells invade into
the uterine endometrium and the endometrial
cells may behave as a reservoir for the
transgene and release it into the invading fetal
cells. Later in pregnancy some non-viral
vectors have been shown to bypass the
placental barrier and viral shedding
transplacentally from maternal circulation
into the fetus may occur (Heikkila et al.,
2001; Kikuchi et al., 2002; Ochiya et al.,
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1999; Okuda et al., 2001; Tsukamoto et al.,
1995). In conclusion, oocytes are well
protected by various elements from the gene
transfer agents. The challenge of on the one
hand preventing the vertical transmission
and, on the other hand, enhancing the
transduction efficiency in germ line cells in
the production of transgenic animals, needs to
be addressed as the methods of genetic
engineering evolve into a clinical course of
treatments. However, even after successful
integration into the genome, the germ line
cells seem to suppress viral promoters, and
the viral genomes may be silenced by the
epigenetic mechanisms such as RNA
interference (Nagano et al., 2002).
Figure 6: Follicular elements protecting the genome of a maturing oocyte.
Numerous cellular projections traverse through the ZP. The space between the ZP and the
oocyte cell membrane is called the perivitelline space. Copyright © 2008 Anniina
Laurema. All rights reserved.
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AIMS OF THE STUDY
In general, the aim was to study the effects of high dose adenoviral gene therapy on the female
reproductive organs and evaluate the risk of vertical transmission and viral distribution into the
offspring.
Detailed aims were
(1) to study the effects of  adenoviral gene therapy during fetal development and to
evaluate the risk of materno-fetal virus transmission (I, II, V);
(2) to study the effect of the gene transfer route on the transgene distribution in the female
uterus and ovaries (I-IV);
(3) to study the effects of reproductive cycling and pregnancy on the distribution of
vectors (II-V);
(4) to compare the effects of baculovirus, plasmid/DOTMA:DOPE and adenovirus
vectors in the ovaries (III, IV)
(5) to study the short-term and long-term effects of suicide gene therapy on fertility and
offspring  (IV-V);
(6) to evaluate the risk of vertical transmission after intra-arterial adenoviral gene therapy
(V).
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MATERIALS AND
METHODS
All methods used are described in detail in
original publications I-V.
Production of vectors. Adenoviruses,
baculoviruses and plasmid/DOTA:DOPE
vectors were used in the studies (Airenne et
al., 2000; Heikkila et al., 2001). E. Coli ß-
galactocidase (LacZ) was used as a marker
gene in distribution studies and herpes
simplex virus thymidine kinase (hsv-TK)
suicide gene in studying the treatment effects
(Kalnins et al., 1983; Sandmair et al., 2000).
The recombinant LacZ gene was combined
with an enhancer element and nuclear
targeting region. A CAG-promoter was used
in all three vectors (adenovirus, baculovirus
and plasmid/DOTMA:DOPE). In hsv-TK
gene construct the CMV promoter was used
with adenoviral and plasmid/DOTMA:DOPE
vectors. All vectors were human clinical
grade vectors.
The replication-deficient
adenoviruses were produced as described in
Hiltunen et al (Hiltunen et al., 2000).
Plasmids were produced in E.Coli and
purified by the Qiagen method. Recombinant
baculoviruses were generated by using the
Bac-To-Bac Baculovirus Expression System
as described by Airenne et al (Airenne et al.,
2000).
Animal model. All studies were
approved by the Experimental Animal
Committee of the University of Kuopio. A
total of 270 animals were used in the study,
from which 108 were adult females and 162
were their progeny (table 2). Two intrauterine
and two intra-arterial gene transfer routes
were studied, the intrauterine routes including
direct gene transfers into the exocoelomic
space in rats (I) and into the uterine lumen in
rabbits at different stages of  the reproductive
cycle (II). For the two intra-arterial routes, a
direct injection was made into the ovarian
arteries in surgery (III) and into the uterine
arteries (IV, V) with an angiographically
guided injection (fig. 6). The two adenoviral
constructions, AdvTK and AdvLacZ, were
studied by both intrauterine (I, II) and intra-
arterial (III-V) methods. The vector dose
(2.6-3.8x108 pfu/kg) used in safety evaluation
was ten times higher than the doses (2.7-
4x108 pfu/kg) used in clinical trials.
Baculovirus vectors were used in the direct
injection into the ovarian artery (III) and
plasmid/DOTMA:DOPE vector in the
injections into the uterine and ovarian arteries
(III, IV).
Fertility studies. Adenoviral
thymidine kinase, AdvTK, gene transfer was
made into the uterine artery of non-pregnant
and pregnant (day 14 p.c.) rabbits.
Ganciclovir was given intravenously on days
3-5 after the gene transfer and the rabbits
were mated again 6 and 12 weeks after the
gene transfer. The rabbit young were born
naturally, and after parturition the rabbits
were given one month for recovery before a
new mating.
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Figure 7: Schematic figure of gene transfer routes and methods.
The roman numerals refer to original publications.
I: Gene transfer into exocoelomic space of rat fetuses during day 14 p.c. was made in open surgery.
The cannula was inserted into the exocoelomic cavity through a tiny hole in chorion.
IIa: Gene transfer into the uterine lumen of normal and pseudopregnant rabbits was made in open
surgery.
IIb: Gene transfer into the uterine lumen of pregnant rabbits was made with ultrasound guided
injection through maternal abdominal wall. The fetal membranes yielded under the tip of the needle.
III: Gene transfer into the ovarian artery was made by cannulation of ovarian artery in open surgery.
IV, V: Gene transfer into uterine artery of pregnant and non-pregnant rabbits was made by
angiographically guided injection into uterine artery.
US = ultrasound sensor, A = amnion, Ch = chorion, F = fetus, P = placenta, UL = uterine lumen, BB =
back bone, a. ovarica = ovarian artery, a. uterine = uterine artery. Copyright © 2008 Anniina Laurema.
All rights reserved.
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Laboratory evaluation. Histochemical and
molecular analytical methods were used for
distribution and safety evaluation studies:
antibody stainings (I-V); PCR (I-V); rt-PCR
(III, V); laser capture micro dissection
(IV,V); sequencing (V) and Southern blotting
(V).
Histological methods. After sacrifice the
tissue samples were removed and processed
by three methods: 1) Immediate freezing in
liquid nitrogen for DNA/RNA extraction, 2)
immersion fixing in paraformaldehyde and
embedding in paraffin for morphological
evaluation and antibody stainings of
histological sections, 3) snap freezing for
LacZ activity evaluation from histological
sections. For microscopic analysis six
different histological stainings were made: 1)
Hematoxylin-eosin (HE) staining was used
for morphological evaluation (Yla-Herttuala
et al., 1990), 2) Xgal staining of frozen
samples was used to note the production of
functional ?-galactosidace in LacZ treated
animals, 3) Ram-11 and 4) T-lymphocyte
antibodies were used for the evaluation of
inflammation, 5) thymidine kinase antibody
and 6) apoptosis stainings were used for the
evaluation of the effects of thymidine kinase
suicide gene therapy (table 3).
Southern Blotting, PCR, rt-PCR, laser
capture microdissection and Sequencing.
DNA and RNA were isolated with Trizol
(Invitrogen). During the tissue and
RNA/DNA isolation procedure the
equipment was cleaned after every sample to
avoid any potential contamination. For laser
capture microdissection analysis, 50 oocytes
were cut from 4 µm thick, hematoxylin
stained deparraffinized histological sections
and DNA was extracted with chloroform-
phenol and used for PCR analysis (fig. 8). In
rt-PCR studies 3 µg of RNA was used for
cDNA synthesis. No positivity was noted in
TK-PCR in the AdvLacZ- transduced
samples and vice versa. In southern blotting
analysis the probes for hsv-TK and LacZ
genes were amplified from corresponding
plasmids using the same primers as with
respective PCRs (table 4, page 54).
Table 3: Histological stainings and their indications.
Staining Target Mechanism Used in
HE All cells Basic staining for morphological evaluation I-V
Xgal ?-galactosidase LacZ enzyme changes galactose to blue colour I-V
LacZ-ab ?-galactosidase Antibody, binds on LacZ transgene product (IV,V)
Ram11-ab macrophage Inflammation marker, binds on macrophages II, III, V
Peroxidase apoptosis Stains apoptotic cell remnants II, III, V
T-lymphocyte T-lymphocytes Inflammation marker, binds on T-lymphocytes IV
TK-ab thymidine kinase Antibody, binds on thymidine kinase (II, IV, V)
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Table 4: PCR primers used in PCR and rt-PCR analysis and their target genes.
PCR Primer Sequence Target region Size
Used
in
*AdvTK I forward 5’-AAA TGG GCG GTA GGC GTG TA-3' 5' UTR 483 bp I, II,
*AdvTK I reverse 5’-AGG CGG TGT TGT GTG GTG TA-3’ TK coding IV,V
AdvTK II forward 5’-AGA AAA TGC CCA CGC TAC TG-3’ TK coding 250 bp V
AdvTK II reverse 5’-GTT ATC TGG GCG CTT GTC AT-3’ TK coding
AdvLacZ I forward 5’-TTG GAG GCC TAG GCT TTT GC-3’ 5' UTR 384 bp II-V
AdvLacZ I reverse 5’-TGA GGG GAC GAC GAC AGT AT-3’ LacZ coding
AdvLacZ I nested f 5'-GGT AGA AGA CCC CAA GGA CTT T-3' 5' UTR 218 bp
AdvLacZ I nested r 5'-CGC CAT TCG CCA TTC AG-3' LacZ coding
AdvLacZ II forward 5’-ACT ATC CCG ACC GCC TTA CT-3’ LacZ coding  175 bp V
AdvLacZ II reverse 5’-CTG TAG CGG CTG ATG TTG AA-3’ LacZ coding
**BacLacZ forward 5’-TTG GCC TAG AGT CGA CGG AT-3’ 5' UTR 219 bp III
**BacLacZ reverse 5’-TGA GGG GAC GAC GAC AGT AT-3’ LacZ coding
**BacLacZ nested f 5’-CCA AGA AGA AAC GCA AAG TG-3’ 5' UTR 190 bp
**BacLacZ nested r 3’-CGC CAT TCG CCA TTC AG-5’ LacZ coding
*For TK plasmid/DOTMA:DOPE PCR AdTK I primers were used in IV.
**For LacZ plasmid/DOTMA:DOPE PCR BacLacZ primers were used in III.
Statistics. GraphPad Prism software was
used for the statistical analysis. T-test with
two-tailed P values was used to evaluate the
significance of the results and P value < 0.05
was considered a significant difference.
Evaluation of inflammation and transduction
efficiency was made by counting cells per
microscopic field.
Figure 8: Laser capture microdissection technique.
With Leica LMD Laser Microdissection device methods (1) single oocytes were cut off from
histological sections (2-4). Arrow head indicates the oocyte and star the hole from isolated oocyte.
Scale bar 50 µm.
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RESULTS AND
DISCUSSION
FETAL GENE TRANSFER
Adenovirus toxicity in fetuses
(Original publications I and V)
Among rat fetuses the survival rate was 52 %
after injection of AdvLacZ into the
exocoelomic cavity. However, the main cause
of fetal death was oligohydramnion caused
by the rupture of the amniotic membrane
during the surgical procedure. Surviving
fetuses exhibited no toxic effects throughout
the follow-up (I).
After injection of adenoviruses into the
uterine artery of pregnant rabbits the mean
litter size 1.8 ± 2.1 was significantly smaller
(P=0.003**) than the normal mean first litter
size 5.6 ± 3.0 in our NZW rabbit colony
(table 5). The litter size was smaller both in
the adenovirus group (AdvLacZ and AdvTK
without ganciclovir) (1.5 ± 1.5, P=0.058, ns)
and significantly smaller in AdvTK combined
with ganciclovir (2.0 ± 1.2, P=0.020*) treated
rabbits (V). The exact mechanism causing the
elevated abortion rate is not fully understood,
but it is commonly known that under stress
the fetal death rate in rabbits is elevated.
Indeed, the anaesthesia combined with the
surgical procedure can be included in such
stressful situations, although toxic effect of
the gene therapy cannot be excluded.
However, as the 9 % rate of stillborn was
much less than the normal 19 % in our rabbit
colony, the stress being behind the
diminished litter size might be more likely
than vector toxicity (V). Moreover, the young
born after the gene transfer were normal on
inspection and also histological analysis
revealed no pathology in the liver, which
would be most likely to be affected through
the umbilical cord blood flow. One
explanation may be the effects outside the
fetus, as the suicide gene therapy may disturb
normal placental function without directly
affecting the fetus. The gene transfer was
made during day 14 p.c. and dead fetuses
may have been absorbed and not included in
the statistical numbers.
Table 5: The litter size and stillborn rate from pregnancies during adenoviral gene transfer into
the uterine artery.
Transfer gene Mean litter
size
Stillborn rate
(n:o of young)
N:o of mothers
(survival %)
Adenovirus control 1.5 ± 1.5 0 % (0/3) 2 (100 %)
AdvTK and ganciclovir 2.0 ± 1.2 13 % (1/8) 4 (100 %)
All 1.8 ± 2.1 9 % (1/11) 6 (100%)
Control 5.6 ± 3.0 19 % 91 (-)
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Materno-fetal leakage
(Original publications I, II and V)
The risk of fetal transmission of a transgene
from the mother seems to depend on the route
of vector administration. In our studies
transplacental leakage of transgene into the
fetal liver was noted via gene transfer into the
maternal uterine circulation (V), in contrast to
no signs of fetal transduction after
intraluminal uterine gene transfer (II). With
PCR analysis transgene DNA was found in
18.2 % of the liver samples of the newborn
young after adenoviral gene transfer into the
uterine circulation during 14th day p.c.(V). In
our previous studies with a similar procedure
on day 14 p.c. using adenovirus and
plasmid:DOTMA/DOPE, the respective
amounts of PCR positive fetuses that were
sacrificed on 17th day p.c., were 50 % and 42
% (Heikkila et al., 2001). From other fetal
samples no vector DNA was noted with PCR,
and the southern blotting analysis indicated
no integrated transgene. Hence,
transplacental transmission of transgene is the
most probable route into the fetal liver via the
umbilical circulation: blood flows from the
placental vessels directly into the fetal liver
and the viral DNA may end up in the liver
cells.
The fetal membranes seem to act as
a barrier for adenoviruses. No transgene
expression was noted in maternal tissues in
rats shortly after adenovirus injection into
fetal cavities (I). The transgene injection into
the exocoelomic cavity between two fetal
membranes, the chorion and the amnion, in
rat fetuses confined the transduction into the
fetal membrane structure called Reichert’s
membrane (fig. 9: A, B, E, page 57). During
gene transfer this membrane surrounded the
developing fetus, but before sacrifice it had
ruptured and retracted around the placenta
(fig. 9: A and fig. 1 page 16). In addition to
exocoelomic injections, some injections
leaked into the uterine lumen causing strong
endometrial transfection (fig. 9: C).
Additionally, adenoviral gene transfer into
the uterine lumen of pregnant rabbits resulted
in strong endometrial gene expression
without any signs of fetal transmission (fig.
9: F) (II). If both chorion and amnion were
penetrated and the transfer gene entered into
the amniotic cavity, the gene expression was
noted in the superficial area of the fetus but
not in maternal tissues (fig. 9: D) (I).
The germ cells migrate from the
exocoelomic cavity into genital ridges until
the 13th day of pregnancy in rats, so the gene
transfer made on day 17 p.c. should not have
reached the germ line cells. As the efficiently
transduced giant cells in Reichert’s
membrane do not exist in humans, these
results obtained with a murine model are not
comparable with a human situation.
VECTOR DISTRIBUTION IN
ADULT FEMALE RABBITS AND
RATS
Uterine tissues and the effect of
reproductive cycling
(Original publications I and II)
With a direct injection of adenoviruses into
the rabbit uterine lumen all uterine tissues
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could be transduced with a reproductive cycle
dependent pattern (II). Viral escape into the
peritoneal cavity through the needle tract
generated a transduction in the outer surface
epithelium of the uterus (fig. 10: A, page 58).
The transduction efficiency in endometrial
epithelium rose parallel to the rising
endometrial activity: In resting stage
endometrium the silent epithelial cells were
not transduced (fig. 10: D) and the viruses
penetrated the uterine muscular tissue
tranducing the smooth muscle cells with a
low efficiency of less than 0.1 % (fig. 10: B).
As the endometrial cells became more active
and the frequency of cell divisions rose, the
virus penetration was restricted to a more
superficial area in the endometrial stroma
(Fig. 10: C). In fully developed, active
endometrium the epithelial cells facing the
lumen were absorbing the gene vector and the
transfection efficiency varied from 0.1-17 %.
(fig. 10: E). Additionally, the active
Figure 9: Adenoviral transduction after gene administration into fetal cavities in rat.
(A) The arrangements of fetal membranes during day 17 p.c. (B, E) After administration into
exocoelomic cavity transfection was restricted to giant cells in Reichert’s membrane. (C) The viral
escape into uterine lumen induced transgene expression in endometrial epithelial cells. (D) Vector
leakage into amniotic cavity transfected the superficial area of the fetus. Xgal staining, blue colour
indicates the transfected cells. Scale bar 200 µm. a = amnion, ch = chorion, e = endometrium, f =
fetus, p = placenta, r = Reichert’s membrane, gc = giant cells. Copyright © 2008 Anniina Laurema.
All rights reserved.
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endometrial epithelial cells in pregnant rats
were expressing the transgene after the
adenoviral escape into uterine lumen during
gene transfer into EC (fig. 10 F) (I).
Although the active uterine
endometrium was efficiently transduced with
adenoviruses, it couldn’t be destroyed by
AdvTK and ganciclovir treatment (II). The
histology of the endometrium of treated and
untreated pseudopregnant rabbits showed a
similar appearance with no change in the rate
of apoptosis or inflammatory cells.
Additionally, with hsv-TK-antibody no
positive cells were noted in the endometrium
six days after the gene transfer (data not
shown). According to pre-existing data the
prodrug ganciclovir penetrates effectively
into endometrial cells and should reach
adequate levels for enhancing the cell death
in the presence of functional thymidine
kinase (Fortin et al., 2004; Henderson et al.,
1993). However, the division frequency of
the epithelial cells seemed to be so high, that
the transfection efficiency of AdvTK became
too low to remove the replicating cells, either
by straight or by bystander effect.
Figure 10: Adenoviral transduction of uterine tissues and the effect of rising endometrial
activity.
Intraperitoneal leakage of adenoviruses affected the outer epithelial cells of the uterus (A). In
inactive endometrium the intraluminal inoculation of adenoviruses resulted in transduction of
deep uterine tissues (A-D). In active endometrium transduction was limited to epithelial cells
(E,F). X-gal staining. Blue colour indicates the transduced cells. Epit. = endometrial
epithelium. Scale bar 50 µm.
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Ovarian tissues and oocytes
(Original publications II, III and IV)
Adenoviral vectors were shown to be able to
transduce all rabbit ovarian tissues via the
circulation, but no vector DNA leakage into
the ovaries through the oviducts was noted
after intraluminal administration into the
uterine lumen (II, III, IV). The transduction
in the ovarian cells after gene transfer into the
uterine artery is supposed to have occurred
via the collateral vessels between the uterine
and ovarian circulation (IV).
The stage of the reproductive cycle
in non-pregnant rabbits affected the
adenoviral transduction rates in ovarian
tissues: also, the transduction pattern differed
between pregnant and non-pregnant rabbits
(Table 6). The transduction efficiency in the
medullar area reached its maximum, 17.1
±.13.5 %, in the thecal cells around the
growing follicles and 15.0 ± 10.6% in the
stromal cells after direct gene transfer into the
ovarian arteries in pseudopregnant rabbits
(Fig. 11: A) (III). In non-pregnant rabbits the
respective amounts were 9.2 ±.10.0 % and
4.8 ± 4.6 % (III). Moreover, the inflammatory
cells and capillary endothelium were
expressing the transgene product. In contrast
to non-pregnant rabbits, insignificant
transduction rates were observed in stromal
cells after vector administration into the
uterine arteries of pregnant rabbits (IV).
The uterine blood flow increases
during pregnancy, and also the collateral
circulation between the uterine and ovarian
arteries is increased by expansion of the
vessels. Additionally, during pregnancy the
luteal glands in the ovaries develop increased
blood flow and the transduction efficiency
after adenoviral injection into the uterine
artery reached 90 % in some luteal glands
compared to 3.2 ± 3.7 % in pseudopregnant
rabbits (fig. 11: B, page 60) (III, IV). In
follicles in the cortical area of the non-
pregnant rabbit ovary, the transduction was
restricted to thecal cells among which the
follicular capillaries circulate (fig. 11: A). In
contrast, in pregnant rabbits the amount of
transduced granulosa cells inside the follicles
was up to 50 % (fig. 11: C) (III, IV).
Table 6: Transfection rates after intra-arterial adenoviral gene transfer in different ovarian cell
lines during different stages in the reproductive cycle.
Ovarian cell line Normal Pseudopr Pregnancy
Primordial oocytes * 0 % 0 % 1±1 %
Maturing oocytes 0 % 0 % 0 %
Granulosa cells 0 % 0 % 0-50 %
Theca cells 9.2±10.0 % 17.1±13.5 % 0-5 %
Stromal cells 4.8±4.6 % 15.0±10.6 % 0 %
Corpus luteum - 3.2±3.7 % 0-90 %
* oocytes lacking the ZP
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In germ cells lacZ staining revealed
transduction in oocytes in 1±1 % of
primordial follicles lacking the ZP shortly
after injection into the uterine arteries of
pregnant rabbits, but in maturing follicles no
transgene expression was noted (fig. 11: D).
In non-pregnant rabbits no signs of transgene
product were observed in the oocytes on
histological staining (III). In PCR analysis of
laser micro-dissected oocytes from
histological sections of ovaries of pregnant
rabbits the vector DNA was noted, verifying
the results obtained from histological analysis
(IV). However, in non-pregnant rabbit
oocytes no signs of vector DNA were
observed after gene transfer via the ovarian
arteries (III).
Comparison of gene vectors
(Original publication II, III and IV)
From the three gene vectors used in these
studies only adenoviruses were efficiently
transducing all ovarian and uterine cells (II-
IV). No detectable expression was noted after
baculoviral administration into the ovarian
circulation in rt-PCR and histological
analysis, but vector DNA was noted from
ovaries, ovuducts and uteruses by PCR (III).
With plasmid:DOTMA/DOPE
vectors only a few positive cells, including a
surprisingly high 9 ± 3 % transfection
efficiency in oocytes, were observed in
histological stainings in ovaries after
inoculation into the uterine arteries in
pregnant rabbits (IV). In contrast, after direct
injection into the ovarian arteries in non-
pregnant rabbits no expression of the LacZ
transgene was noted in oocytes and only
isolated cells in ovarian stromal tissues were
expressing the transgene product (III).
However, in PCR analysis vector DNA was
noted from all reproductive tract tissues and
the liver, implicating wide systemic
distribution after intra-arterial inoculation
(III, IV). Additionally, vector DNA was also
noted in oocytes after injection of
TK/DOTMA:DOPE into the uterine arteries
of pregnant rabbits, as confirmed by laser
capture microdissection (IV). In conclusion,
the pregnancy seems to influence the ability
of plasmid:DOTMA/DOPE vectors to
penetrate into oocytes.
Figure 11: Adenoviral transfection of ovarian
tissues.
In non-pregnant ovaries transduction was
limited in stromal and thecal cells (A). In
pregnant ovaries transfection of luteal (B),
granulosa (C) cells and rarely primordial
oocytes (D) were noted. Xgal staining, blue
colour indicates the transduced cells. Scale
bar 100 µm.
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EFFECTS OF SUICIDE GENE
THERAPY ON FERTILITY
Short term effects on oocytes
(Original publication IV)
Morphological changes were noted in the
oocytes in primordial follicles lacking the
zona pellucida shortly after administration of
AdvTK combined with ganciclovir into the
uterine arteries of pregnant rabbits (IV).
Indeed, the number of primordial follicles
counted from histological sections was
diminished compared with normal ovaries
and the morphology was abnormal in 23± 11
% of the remaining oocytes (fig. 12). After a
similar gene transfer procedure with
TK:DOTMA/DOPE vectors combined with
ganciclovir less radical changes were noted in
28 ± 13 % of similar stage oocytes, without
diminution in number of the primordial
follicles (fig. 12) (IV). Also, AdvTK DNA
was noted from laser microdissected oocytes
in PCR analysis of both adenovirus and
DOTMA/DOPE treated animals.
The exact mechanism causing the
changes in oocytes remains unknown. The
amount of cells that were affected with
AdvTK (28 ± 13 % ) does not correlate with
the amount of transduced cells observed after
AdvLacZ (1 ± 1 %) administration via the
uterine artery. The oocytes in the primordial
follicles are tightly connected to the
surrounding granulosa cells with gap
junctions, which allow exchange of small
molecules, such as the toxic metabolite of
ganciclovir. Hence, the changes in the
oocytes may have been caused by bystander
effect without the transduction of the oocytes
themselves.
Long-term studies and risk of vertical
transmission
(Original publications IV and V)
The short-term morphological changes in
oocytes in primordial follicles, noted from
histological sections eight days after the gene
Figure 12: Short-term effects in oocytes in
primordial follicles after AdvTK and
ganciclovir gene therapy.
Oocytes are indicated by arrow heads. After
TK/DOTMA:DOPE/ganciclovir treatment
morphology of the nuclei of oocytes were
vestigial compared with controls. In
AdTKv/ganciclovir treated ovaries the number
of oocytes was diminished and remnants of
atrophied primary follicles were seen (star).
HE staining, scale bar 100µm.
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transfer, were not observed during later time
points from one to three months after gene
transfer (IV, V). Also, the litter sizes and
numbers of stillborn young in treated animals
in matings made six and twelve weeks after
the AdvTK and ganciclovir therapy did not
significantly differ from the numbers in our
untreated rabbit colony (table 7).
All young born were normal by
inspection and also they developed without
abnormalities. A total of 9.3 % of the livers
of the liveborn young from the matings made
at six and twelve weeks after the
intravascular adenoviral gene transfer to
rabbit mothers, were found positive for
transgene DNA in PCR analysis (V).
The reproductive status (pregnant or non-
pregnant) of the mother during gene transfer
affected the occurrence of maternal-fetal
transgene leakage in subsequent pregnancies.
This is shown by the fact that the respective
amounts of transgene positive liver samples
of the young born from the matings made six
and twelve weeks after the gene transfer,
were 11 % and 10 % in pregnant animals and
5 % and 0 % in non-pregnant animals (table
8). However, the total numbers of PCR
positive young from matings made six weeks
and twelve weeks after the gene transfer were
diminishing over time (8.7 % and 6.7 %.,
respectively).
Table 7: Mean litter sizes from matings made six and twelve weeks after gene transfer and
stillborn rates.
Transgene Mean litter size
6 weeks
Mean litter size
12 weeks
Stillborn rate
(n:o of young)
AdvTK and ganciclovir 6.8 ± 0.9 9.7 ± 2.0 21 % (70)
Adenovirus control 6.7 ± 1.2 4.3 ± 1.8 27 % (33)
Normal control 7.0 ± 2.5 7.4 ± 2.3 19 %
Table 8: Effect of reproductive status on transgene leakage into progeny in subsequent matings
made six and twelve weeks after adenoviral gene transfer.
Status of the mother
during gene transfer
PCR positive progeny
(n:o of liveborn young)
6 weeks time-point
PCR positive progeny
(n:o of liveborn young)
12 weeks time-point
Pregnant 11 % (27) 10 % (20)
Non-pregnant 5 % (19) 0 % (10)
All 8.7 % (36) 6.7 % (30)
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PCR analysis from fetal tissues other than the
liver revealed no positivity for vector DNA.
Also, no transgene expression was noted in
rtPCR analysis, and southern blotting did not
indicate integration of the transgene. This
result may indicate transplacental leakage of
the transgene from the maternal uterine
tissues via the umbilical circulation rather
than vertical transmission via the germ line,
as already indicated in the materno-fetal
leakage section. The maternal endometrium
may behave as storage for viral DNA and
during placentation the DNA is released into
invading trophoblastic cells. During later
pregnancy the transplacental blood
contamination may also occur. On the other
hand, the vector DNA may have been located
episomally inside the oocyte, or in the
perivitelline space to be internalized during
fertilization leading to the presence of vector
DNA in the fetal liver. In any case, the
number of PCR positive young was
diminishing during the follow-up, which may
be due to a reducing amount of transgene in
either the uterine endometrium or in the
oocyte contents.
The long term results indicate that
the short term changes in oocytes seem to be
transient resulting in no effect on later
fertility and the quality of the young. As one
reproductive cycle lasts 18 days in rabbits, at
least two or three generations of primordial
follicles underwent the complete maturation
process during the follow-up. The amount of
ganciclovir may have been too low to cause
the complete destruction of oocytes. On the
other hand, the quiescent nature of resting
oocytes may have prevented the toxic action
of the TK/ganciclovir therapy and even if the
ganciclovir were transformed into its active
metabolites, these may have been flushed out
of the cell before new activation during
maturation and fertilization. Moreover, the
transgene may be silenced during
development and the active transgene product
would never be produced.
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SUMMARY AND
CONCLUSIONS
All tissues in uterus and ovaries could be
transduced with adenoviral vectors, although
the transfection efficiency in the oocytes was
less than 1 %. The risk of vertical
transmission via the germ line into the
offspring was highly unlikely, although
maternal-fetal vector leakage after intra-
arterial administration could not be excluded.
(1) The materno-fetal leakage of the
adenoviral vector seems to be prevented by
the fetal membranes, but transplacental
escape of the transgene may occur.
Administration of adenoviruses into rabbit
uterine lumen did not cause transduction in
the tissues of the developing fetuses and vice
versa, the gene transfer into the exocoelomic
cavity of rat fetuses did not affect the
maternal tissues. However, the gene
expression in the exocoelomic cavity of the
rat fetuses was restricted to murine fetal
membrane not found in humans, which
reduces the utility value of the result
concerning human studies. After adenovirus
administration into the uterine circulation in
rabbits, the vector DNA was observed in
PCR analysis from the livers of rabbit
fetuses, but not from other fetal tissues
indicating transplacental transmission of the
transgene. In addition, vector DNA was noted
from PCR analysis from the liver samples of
the young born from the matings made three
months after the maternal gene transfer.
However, no signs of integration of the
transgene were noted in the progeny,
verifying no contamination of the germ line.
(2) All ovarian and uterine tissues could be
transduced with adenoviral vectors and the
transduction pattern varied with the
administration route. Via intrauterine routes
the transgene expression was restricted into
the uterine contents and did not affect the
ovaries. In contrast, via the intra-arterial gene
transfer routes, either uterine or ovarian
artery, vector DNA spread into all uterine,
oviductal and ovarian tissues. The most
widespread and efficient gene expression in
the ovaries was noted in thecal and stromal
cells after direct injection into the ovarian
artery of non-pregnant rabbits. Additionally,
shortly after adenoviral gene transfer during
pregnancy the transgene expression in the
primordial oocytes was rarely noted.
(3) The stage of reproductive cycling had a
strong effect on the transduction pattern
especially in uterine tissues but also in the
ovary. During the inactive stage low
transduction of deep uterine tissues, such as
uterine muscle and endometrial stroma, was
observed in contrast to high, but transient
transgene expression in the endometrial
epithelium during the proliferative stage.
Similarly, in ovarian tissues the transfection
efficiency was affected by the reproductive
cycling, the transfection efficiency being
higher in pseudopregnant rabbits than in non-
pregnant ones. In non-pregnant rabbits the
thecal and stromal cells were efficiently
transduced with no signs of any
intrafollicular transgene effect. In contrast,
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during pregnancy the transgene expression
was noted in follicular cells and oocytes with
low efficiency and in luteal cells with varying
efficiency which is likely due to modification
of the blood vessel system.
(4) With baculovirus and
plasmid/DOTMA:DOPE vectors a very low
transfection efficiency compared to
adenoviruses was noted in the ovarian tissues
after administration into the ovarian
circulation. However, a rather high
occurrence of transgene expression in oocytes
with plasmid/DOTMA:DOPE vectors during
pregnancy was observed. It can be concluded
that these vectors are not suitable for gene
therapy in reproductive organs.
(5) Shortly after intra-arterial administration
of adenoviral suicide gene therapy into the
uterine circulation, morphological changes
were observed in oocytes in primordial
follicles in histological samples. In addition,
suicide gene DNA was observed in DNA
extracted from oocytes dissected by laser
capture microdissection. However, these
changes seemed to be transient and the
fertility of the rabbits was not reduced, as
normal litter sizes with non-significantly
higher stillborn rates and normal young were
obtained from repeated matings of the treated
mothers compared with normal controls.
(6) The risk of vertical transmission of
adenoviral gene therapy seemed to be very
low, as no signs of integration of transgene
were noted. However, the materno-fetal
leakage of vector DNA could not be excluded
in the months following the gene transfer, as
during long-term follow up a diminishing
amount of vector DNA positive young were
born from matings made to treated rabbit
mothers six and twelve weeks after the gene
transfer.
In conclusion, adenoviral gene therapy did
not affect fertility or fetal health, although
distribution into female germ cells could not
be excluded. The effects and distribution of
gene vectors in the female reproductive
organs were affected by the route of
administration, the stage of the reproductive
cycle and the gene vector combination. These
should be noted in safety studies of gene
therapies targeted at patients with
reproductive ability. In future, further
development of specific and sensitive
analysis methods and their use with relevant
animal models are needed for reliable
preclinical safety evaluation.
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